Akari Therapeutics (AKTX) S-4/A 30 Sep 24 Registration of securities issued in business combination transactions (amended) Financial data

Cover Page

Cover Page	6 Months Ended
	Jun. 30, 2024
Document Information [Line Items]
Document Type	S-4/A
Amendment Flag	true
Amendment Description	Amendment No. 1
Entity Registrant Name	AKARI THERAPEUTICS, PLC
Entity Central Index Key	0001541157
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	X0
Entity Tax Identification Number	98-1034922
Entity Address, Address Line One	22 Boston Wharf Road
Entity Address, Address Line Two	FL 7
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
City Area Code	929
Local Phone Number	274-7510
Entity Primary SIC Number	2834
Business Contact [Member]
Document Information [Line Items]
Entity Address, Address Line One	Puglisi & Associates 850 Library Avenue
Entity Address, City or Town	Newark
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19711
City Area Code	302
Local Phone Number	738-6680

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 4,177	$ 3,845	$ 13,250
Prepaid expenses	805	299	465
Other current assets	94	197	100
Total current assets	5,076	4,341	13,815
Patent acquisition costs, net		14	17
Total assets	5,076	4,355	13,832
Current liabilities:
Accounts payable	4,686	1,671	947
Accrued expenses	1,685	1,566	3,148
Convertible notes, related party	1,000
Warrant liability	755	1,253	7,852
Other current liabilities	653	94	94
Total liabilities	8,779	4,584	12,041
Commitments and contingencies (Note 9)
Shareholders' deficit:
Share capital of $0.0001 par value Authorized: 45,122,321,523 ordinary shares at June 30, 2024 and December 31, 2023, respectively; issued and outstanding: 24,289,232,698 and 13,234,315,298 at June 30, 2024 and December 31, 2023, respectively	2,430	1,324	745
Additional paid-in capital	183,007	174,754	167,076
Capital redemption reserve	52,194	52,194	52,194
Accumulated other comprehensive loss	(749)	(1,040)	(771)
Accumulated deficit	(240,585)	(227,461)	(217,453)
Total shareholders' deficit	(3,703)	(229)	1,791
Total liabilities and shareholders' deficit	$ 5,076	$ 4,355	$ 13,832

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical)	Jun. 30, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares
Statement of Financial Position [Abstract]
Ordinary shares, par value | (per share)	$ 0.0001	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	45,122,321,523	45,122,321,523	15,000,000,000
Ordinary shares, shares issued	24,289,232,698	13,234,315,298	7,444,917,123
Ordinary shares, shares outstanding	24,289,232,698	13,234,315,298	7,444,917,123

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 3,314	$ 1,524	$ 5,593	$ 3,255	$ 5,450	$ 9,561
General and administrative	2,241	3,091	4,907	5,954	11,356	13,527
Merger-related costs	254		1,298
Restructuring and other costs	1,640		1,640
Loss from operations	(7,449)	(4,615)	(13,438)	(9,209)	(16,806)	(23,088)
Other income (expense):
Interest income	2	29	4	59	82	46
Interest expense	(51)		(51)
Excess in fair value of warrant liability over cash proceeds						(1,963)
Change in fair value of warrant liability	(151)	560	498	6,147	6,599	6,946
Foreign currency exchange gain (loss), net	91	39	(135)	28	136	453
Other expense, net		(13)	(2)	(24)	(19)	(142)
Total other income (expense), net	(109)	615	314	6,210
Net loss	$ (7,558)	$ (4,000)	$ (13,124)	$ (2,999)	$ (10,008)	$ (17,748)
Net loss per share - basic	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Net loss per share - diluted	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Weighted-average number of ordinary shares used in computing net loss per share- basic	18,836,478,977	16,144,813,478	10,115,005,727	8,787,337,361	9,788,980,193	6,243,462,410
Weighted-average number of ordinary shares used in computing net loss per share - diluted	18,836,478,977	16,144,813,478	10,115,005,727	8,787,337,361	9,788,980,193	6,243,462,410
Comprehensive loss:
Net loss	$ (7,558)	$ (4,000)	$ (13,124)	$ (2,999)	$ (10,008)	$ (17,748)
Other comprehensive income, net of tax:
Foreign currency translation adjustment	12	(57)	291	(55)	(269)	(230)
Total other comprehensive income, net of tax	12	(57)	291	(55)	(269)	(230)
Total comprehensive loss	$ (7,546)	$ (4,057)	$ (12,833)	$ (3,054)	$ (10,277)	$ (17,978)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Share Capital	Additional Paid-in Capital	Capital Redemption Reserve	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at beginning of the year at Dec. 31, 2021	$ 5,555	$ 476	$ 153,131	$ 52,194	$ (541)	$ (199,705)
Balance at the beginning of the year (in shares) at Dec. 31, 2021		4,759,731,923
Issuance of share capital related to financing, net of issuance costs	13,479	$ 269	13,210
Issuance of share capital related to financing, net of issuance costs (in shares)		2,685,185,200
Share-based compensation	735		735
Foreign currency translation	(230)				(230)
Net loss	(17,748)					(17,748)
Balance at the end of the year at Dec. 31, 2022	1,791	$ 745	167,076	52,194	(771)	(217,453)
Balance at the end of the year (in shares) at Dec. 31, 2022		7,444,917,123
Issuance of share capital related to financing, net of issuance costs	3,502	$ 267	3,235
Issuance of share capital related to financing, net of issuance costs (in shares)		2,666,666,700
Share-based compensation	265		265
Foreign currency translation	2				2
Net loss	1,001					1,001
Balance at the end of the year at Mar. 31, 2023	6,561	$ 1,012	170,576	52,194	(769)	(216,452)
Balance at the end of the year (in shares) at Mar. 31, 2023		10,111,583,823
Balance at beginning of the year at Dec. 31, 2022	1,791	$ 745	167,076	52,194	(771)	(217,453)
Balance at the beginning of the year (in shares) at Dec. 31, 2022		7,444,917,123
Net loss	(2,999)
Balance at the end of the year at Jun. 30, 2023	2,781	$ 1,013	170,852	52,194	(826)	(220,452)
Balance at the end of the year (in shares) at Jun. 30, 2023		10,122,321,523
Balance at beginning of the year at Dec. 31, 2022	1,791	$ 745	167,076	52,194	(771)	(217,453)
Balance at the beginning of the year (in shares) at Dec. 31, 2022		7,444,917,123
Issuance of share capital related to financing, net of issuance costs	6,961	$ 567	6,394
Issuance of share capital related to financing, net of issuance costs (in shares)		5,666,034,700
Issuance Of Share Capital Shares For Vendor Services		80,000,000
Issuance Of Share Capital Value For Vendor Services	142	$ 8	134
Vesting of restricted shares	4	$ 4
Vesting of restricted shares (in shares)		43,363,475
Share-based compensation	1,150		1,150
Foreign currency translation	(269)				(269)
Net loss	(10,008)					(10,008)
Balance at the end of the year at Dec. 31, 2023	(229)	$ 1,324	174,754	52,194	(1,040)	(227,461)
Balance at the end of the year (in shares) at Dec. 31, 2023		13,234,315,298
Balance at beginning of the year at Mar. 31, 2023	6,561	$ 1,012	170,576	52,194	(769)	(216,452)
Balance at the beginning of the year (in shares) at Mar. 31, 2023		10,111,583,823
Vesting of restricted shares	1	$ 1
Vesting of restricted shares (in shares)		10,737,700
Share-based compensation	276		276
Foreign currency translation	(57)				(57)
Net loss	(4,000)					(4,000)
Balance at the end of the year at Jun. 30, 2023	2,781	$ 1,013	170,852	52,194	(826)	(220,452)
Balance at the end of the year (in shares) at Jun. 30, 2023		10,122,321,523
Balance at beginning of the year at Dec. 31, 2023	(229)	$ 1,324	174,754	52,194	(1,040)	(227,461)
Balance at the beginning of the year (in shares) at Dec. 31, 2023		13,234,315,298
Issuance of share capital related to financing, net of issuance costs	1,664	$ 264	1,400
Issuance of share capital related to financing, net of issuance costs (in shares)		2,641,228,000
Vesting of restricted shares	3	$ 10	(7)
Vesting of restricted shares (in shares)		97,578,000
Share-based compensation	296		296
Foreign currency translation	279				279
Net loss	(5,566)					(5,566)
Balance at the end of the year at Mar. 31, 2024	(3,553)	$ 1,598	176,443	52,194	(761)	(233,027)
Balance at the end of the year (in shares) at Mar. 31, 2024		15,973,121,298
Balance at beginning of the year at Dec. 31, 2023	(229)	$ 1,324	174,754	52,194	(1,040)	(227,461)
Balance at the beginning of the year (in shares) at Dec. 31, 2023		13,234,315,298
Net loss	(13,124)
Balance at the end of the year at Jun. 30, 2024	(3,703)	$ 2,430	183,007	52,194	(749)	(240,585)
Balance at the end of the year (in shares) at Jun. 30, 2024		24,289,232,698
Balance at beginning of the year at Mar. 31, 2024	(3,553)	$ 1,598	176,443	52,194	(761)	(233,027)
Balance at the beginning of the year (in shares) at Mar. 31, 2024		15,973,121,298
Issuance of share capital related to financing, net of issuance costs	6,951	$ 806	6,145
Issuance of share capital related to financing, net of issuance costs (in shares)		8,059,508,000
Vesting of restricted shares		$ 29	(29)
Vesting of restricted shares (in shares)		285,697,400
Share-based compensation	445		445
Foreign currency translation	12				12
Net loss	(7,558)					(7,558)
Balance at the end of the year at Jun. 30, 2024	$ (3,703)	$ 2,430	183,007	$ 52,194	$ (749)	$ (240,585)
Balance at the end of the year (in shares) at Jun. 30, 2024		24,289,232,698
Issuance of share capital for services		$ 9	(9)
Issuance of share capital for services (in shares)		91,396,000
Shares withheld for payroll taxes		$ (12)	$ 12
Shares withheld for payroll taxes (in shares)		(120,490,000)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Parenthetical)	Jun. 30, 2024 $ / shares	Mar. 31, 2024 $ / shares	Dec. 31, 2023 $ / shares	Aug. 17, 2023 $ / shares	Jun. 30, 2023 $ / shares	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares	Dec. 31, 2020 $ / shares	Dec. 31, 2020 £ / shares
Statement of Stockholders' Equity [Abstract]
Share capital, par value | (per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	£ 0.01

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (13,124)	$ (2,999)	$ (10,008)	$ (17,748)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13	2	4	4
Share-based compensation	741	541	1,150	735
Issuance of share capital for vendor services			142
Excess fair value of warrant liability over cash proceeds				1,963
Change in fair value of warrant liability	(498)	(6,147)	(6,599)	(6,946)
Foreign currency exchange losses (gains)	280	(34)	(255)	(334)
Change in assets and liabilities:
Prepaid expenses and other current assets	702	(269)	70	1,699
Accounts payable and accrued expenses	2,948	(668)	(936)	(877)
Net cash used in operating activities	(8,938)	(9,574)	(16,432)	(21,504)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares, net of issuance costs	8,820	3,502	7,016	25,194
Proceeds from issuance of convertible notes	1,000
Proceeds from employee vesting of restricted shares	3	1	4
Payments on short-term financing arrangement	(546)
Proceeds from exercise of warrants to purchase shares				94
Net cash provided by financing activities	9,277	3,503	7,020	25,288
Effect of exchange rates on cash	(7)	2	7	105
Net increase (decrease) in cash	332	(6,069)	(9,405)	3,889
Cash at beginning of period	3,845	13,250	13,250	9,361
Cash at end of period	4,177	$ 7,181	3,845	13,250
SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES:
Financing costs in accrued expenses	205		$ 55
Non-cash seller-financed purchases	1,105
Ordinary share subscription deposit				1,120
Initial valuation of warrant liability				$ 14,798
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFO:
Cash paid during the period for interest	$ 51

Description of Business

Description of Business	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Description of Business
Description of Business	Note 1. Description of Business Business Overview Akari Therapeutics, Plc, (the “Company” or “Akari”) is incorporated in the United Kingdom. The Company is a biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving the complement component 5 (“C5”) and leukotriene B4 (“LTB4”) pathways. The Company’s activities since inception have consisted of performing research and development activities and raising capital. The Company is subject to a number of risks similar to those of preclinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with preclinical trials of products, dependence on third-party collaborators for research and development operations, need for marketing authorization of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts and clinical and regulatory activities. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities. Agreement and Plan of Merger As further described in Note 3, in March 2024, the Company entered into an Agreement and Plan of Merger with Peak Bio, Inc. (“Peak Bio”). However, the Merger has not yet closed. The Company expects to close the merger in the fourth quarter of 2024. Liquidity and Financial Condition The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-40, Presentation of Financial Statements—Going Concern The Company has incurred substantial losses and negative cash flows since inception and had an accumulated deficit of $240.6 million as of June 30, 2024. The Company’s cash balance of $4.2 million as of June 30, 2024 is not sufficient to fund its operations for the one-year The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as uncertainty of clinical trial outcomes, uncertainty of additional funding, and history of operating losses. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates. Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include, but are not limited to: product development financing, private placements and/or public offerings of equity and/or debt securities, and strategic research and development collaborations and/or similar arrangements. There can be no assurance that these future funding efforts will be successful. Nasdaq Continued Listing Rules On April 5, 2024, the Company received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that the Company’s shareholders’ equity as reported in its Form 10-K 10-K, In accordance with the Nasdaq Listing Rules, on May 20, 2024, the Company submitted a plan to regain compliance with the Stockholders’ Equity Requirement (the “Compliance Plan”) for the Staff’s consideration. On August 5, 2024, the Company was notified by the Staff that it has been granted an extension until September 30, 2024 to comply with the Compliance Plan and evidence compliance with the Minimum Equity Requirement. There can be no assurance that the Company will be able to evidence compliance with the Shareholders’ Equity Requirement during the extension period granted by the Staff. In the event the Company does not satisfy the terms of the Nasdaq Notice and evidence compliance with the Shareholders’ Equity Requirement, the Staff will provide written notification that the Company’s securities will be delisted. The Company would, at that time, be entitled to request a hearing before a Nasdaq Hearings Panel to present its Compliance Plan to regain compliance and to request a further extension period to regain compliance with the Shareholders’ Equity Requirement. The request for a hearing would stay any delisting action by the Staff.	Note 1. Description of Business Business Overview Akari Therapeutics, Plc, (the “Company” or “Akari”) is incorporated in the United Kingdom. The Company is a clinical-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The Company’s activities since inception have consisted of performing research and development activities and raising capital. The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research and development operations, need for marketing authorization of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts and clinical and regulatory activities. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities. Agreement and Plan of Merger As further described in Note 10, in March 2024, the Company entered into an Agreement and Plan of Merger with Peak Bio, Inc. Following the anticipated closing of the Merger (as defined below), we expect to have an expanded pipeline that contains multiple compelling assets spanning early and late development stages with the addition of Peak Bio Inc.’s Phase 2-ready PHP-303 alpha-1 Liquidity and Financial Condition The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-40, Presentation of Financial Statements—Going Concern The Company has incurred substantial losses and negative cash flows since inception and had an accumulated deficit of $227.5 million as of December 31, 2023. The Company’s cash balance of $3.8 million as of December 31, 2023 is not sufficient to fund its operations for the one-year The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as uncertainty of clinical trial outcomes, uncertainty of additional funding, and history of operating losses. Substantial additional financing will be needed by the Company to fund its operations and to commercially develop its product candidates. Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include, but are not limited to: product development financing, private placements and/or public offerings of equity and/or debt securities, and strategic research and development collaborations and/or similar arrangements. There can be no assurance that these future funding efforts will be successful. Nasdaq Continued Listing Rules On October 24, 2022, the Company received a deficiency notification letter from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s Common Stock had closed below $1.00 per share (the “Minimum Bid Requirement”) for the previous thirty consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days from the date of such notice, or until April 24, 2023, to regain compliance with the Minimum Bid Requirement. To regain compliance, the bid price for the Company’s American Depository Shares (“ADSs”) must have closed at $1.00 per share or more for a minimum of ten consecutive business days. On April 25, 2023, the Staff granted the Company an additional 180 calendar day period, or until October 23, 2023, in which to regain compliance with the Minimum Bid Requirement. Following the successful completion of the ADS Ratio Change (defined below), the Company received a written notice from the Staff that it has regained compliance with the Minimum Bid Requirement as a result of the Company’s ADSs having a closing bid price of $1.00 per share or greater for 10 consecutive business days. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain shareholders’ equity of at least $2.5 million (the “Shareholders’ Equity Requirement”). As of December 31, 2023, the Company had a shareholders’ deficit of $0.2 million and therefore is not in compliance with the Shareholders’ Equity Requirement. If the Company continues to not be in compliance or it fails to meet any of the other Nasdaq continuing listing requirements, its ADSs may be subject to delisting and the Company may become subject to delisting proceedings. The Company is currently assessing its available options to regain compliance with the Shareholders’ Equity Requirement. ADS Ratio Change Effective August 17, 2023, the Company changed the ratio of its ADSs to ordinary shares, par value $0.0001 per share, from one ADS representing 100 ordinary shares to a new ratio of one ADS representing 2,000 ordinary shares (the “ADS Ratio Change”). All ADS and per ADS amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the ADS Ratio Change.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of presentation 10-K, Principles of consolidation – Foreign currency – The reporting currency of the Company is U.S. dollars. The financial statements of certain of the Company’s foreign subsidiaries are measured using their local currency as the functional currency. The Company translates its non-U.S. Use of estimates – Concentration of credit risk – Fair value measurements Fair Value Measurements and Disclosures • Level 1 • Level 2 • Level 3 Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. The fair value hierarchy also requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company’s cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The Company’s liability-classified warrants are recorded at their estimated fair value. See Note 4. Cash – Prepaid expenses – Other current assets Patent acquisition costs Accrued expenses pre-clinical Convertible Notes The Company accounts for convertible promissory notes in accordance with ASC Topic 470-20, Debt with Conversion and Other Options 470-20”) Warrant Liability Distinguishing Liabilities from Equity Derivatives and Hedging paid-in In connection with the sale of the ADSs in the September 2022 Registered Direct Offering, the Company issued to the investors registered Series A warrants (“Series A Warrants”) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS and registered Series B warrants (“Series B Warrants”) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS (collectively, the “September 2022 Warrants”).The Company determined that the September 2022 Warrants are not indexed to the Company’s own stock in the manner contemplated by ASC 815-40-15, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock Other Current Liabilities Research and development expenses – Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven cash flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company’s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the condensed consolidated statements of operations and comprehensive loss. Merger-Related Costs – Restructuring and Other Costs – reduction-in-force HSCT-TMA reduction-in-force reduction-in-force, HSCT-TMA non-cash As of June 30, 2024, of the $1.6 million total restructuring-related charges incurred, $0.5 million was unpaid and included in accrued expenses in the accompanying condensed consolidated balance sheet. See Note 5. The Company expects these costs to be payable through the fourth quarter of 2024. Share-based compensation expense – non-employees The fair value of each restricted ordinary share award is determined on the date of grant based on the fair value of the Company’s ordinary shares on that same date. The fair value of each share option grant is determined on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. See Note 7. The Company estimates stock price volatility based on the Company’s historical stock price performance over a period of time that matches the expected term of the stock options. The expected term of the Company’s options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future. Leases – Leases right-of-use Income taxes Interim Reporting Income Taxes year-to-date Net loss per share pre-funded The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: As of June 30, 2024 2023 Stock options 351,934,688 680,112,400 Restricted stock units 251,823,915 418,580,700 Warrants 13,191,074,600 4,155,347,500 Convertible notes 1,257,860,000 —  Total 15,052,693,203 5,254,040,600 New Accounting Pronouncements Recently Issued (Not Yet Adopted) Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures	Note 2. Summary of Significant Accounting Policies Basis of presentation Principles of consolidation – Foreign currency – The reporting currency of the Company is U.S. dollars. The Company translates its non-U.S. Use of estimates – Segments Concentration of credit risk – Fair value measurements Fair Value Measurements and Disclosures • Level 1 • Level 2 • Level 3 Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. The fair value hierarchy also requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company’s cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The Company’s liability-classified warrants are recorded at their estimated fair value. See Note 3. Cash – Prepaid expenses – Other current assets Patent acquisition costs Accrued expenses pre-clinical Warrant Liability Distinguishing Liabilities from Equity Derivatives and Hedging paid-in Research and development expenses – Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven cash flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company’s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the consolidated statements of operations and comprehensive loss. Stock-based compensation expense – non-employees The fair value of each restricted ordinary share award is determined on the date of grant based on the fair value of the Company’s ordinary shares on that same date. The fair value of each share option grant is determined on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends (See Note 6). Beginning on January 1, 2023, the Company began using its historical stock price volatility to determine the volatility assumption to be used in its Black-Scholes option pricing model. Prior to January 1, 2023, the Company estimated its expected stock price volatility based on the historical volatility of publicly traded peer companies. The expected term of the Company’s options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future. Leases – Leases right-of-use Income taxes The Company follows the provisions of ASC 740 “ Accounting for Uncertainty in Income Taxes de-recognition, Accounting for Uncertainty in Income Taxes “more-likely-than-not” Comprehensive Income (Loss) non-owner Net loss per share pre-funded For periods in which the Company has reported net losses, diluted net loss per ordinary share is the same as basic net loss per ordinary share, since dilutive ordinary shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss for each of the years ended December 31, 2023 and 2022. The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: Year Ended December 31, 2023 2022 Stock options 651,237,400 513,673,885 Restricted stock units 385,954,925 21,475,400 Warrants 4,240,447,500 4,155,347,500 Total 5,277,639,825 4,690,496,785 New Accounting Pronouncements Recently Issued (Not Yet Adopted) Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures

Agreement and Plan of Merger

Agreement and Plan of Merger	6 Months Ended
	Jun. 30, 2024
Agreement And Plan Of Merger [Abstract]
Agreement and Plan of Merger	Note 3. Agreement and Plan of Merger Agreement and Plan of Merger On March 4, 2024, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Peak Bio and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (“Pegasus Merger Sub”), pursuant to which, upon the terms and subject to the conditions thereof, Pegasus Merger Sub will be merged with and into Peak Bio (the “Merger”), with Peak Bio surviving the Merger as a wholly-owned subsidiary of Akari. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the “Effective Time”), each issued and outstanding share of Peak Bio common stock, par value $0.0001 per share (the “Peak Common Stock”) (other than (x) shares of Peak Common Stock held by Peak Bio as treasury stock, or shares of Peak Common Stock owned by Akari, Pegasus Merger Sub or any direct or indirect wholly-owned subsidiaries of Akari and (y) Dissenting Shares (as defined in the Merger Agreement), will be converted into the right to receive the Company’s ADSs representing a number of Akari ordinary shares, par value $0.0001 per share (the “Akari Ordinary Shares”) equal to an exchange ratio calculated in accordance with the Merger Agreement (the “Exchange Ratio”), each such share duly and validly issued against the deposit of the requisite number of Akari Ordinary Shares in accordance with the Deposit Agreement (as defined in the Merger Agreement). The Exchange Ratio will be calculated such that the total number of shares of Akari ADSs to be issued as merger consideration for the Peak Common Stock will be expected to be, upon issuance, approximately 50% of the outstanding shares of Akari ADSs (provided, certain adjustments to this ratio will be made in respect of the net cash, as determined in accordance with the Merger Agreement, of each of Akari and Peak Bio at the close of business one business day prior to the anticipated consummation of the Merger). The Merger Agreement provides that, under certain circumstances, additional Akari ADSs may be issued to the holders of shares of Peak Common Stock following the consummation of the Merger equal to an exchange ratio calculated in accordance with the Merger Agreement (the “Additional Exchange Ratio”). The board of directors of each of Akari and Peak has unanimously approved the Merger Agreement and the transactions contemplated thereby. Consummation of the Merger is subject to various conditions, including, among others, (i) approval of the Merger Agreement and Merger by Peak Bio stockholders, (ii) Akari’s shareholders authorizing Akari’s board of directors to allot all Akari ordinary shares to be issued in connection with the Merger (to be represented by Akari ADSs), (iii) the absence of any law or order prohibiting consummation of the Merger, (iv) Akari’s Registration Statement on Form S-4 Either Akari or Peak Bio may terminate the Merger Agreement under certain circumstances, including if (i) the Merger is not completed by December 2, 2024, (ii) the other party’s board of directors withdraws, modifies or qualifies its recommendation in favor of the transactions contemplated by the Merger Agreement or approves or recommends an alternative transaction or (iii) Akari’s or Peak Bio’s board of directors, as applicable, resolves to enter into a definitive agreement with respect to a superior proposal prior to obtaining approval of the Akari ADS issuance or Merger, as applicable, from Akari’s shareholders or Peak Bio’s stockholders, as applicable. The Merger Agreement also provides that under certain specified circumstances of termination described in the Merger Agreement, Akari or Peak Bio, as applicable, will be required to pay a termination fee equal to $300,000 and reimburse the other party for expenses related to the transaction up to $1.5 million. Concurrently with the Merger Agreement, Akari and Peak Bio entered into voting and support agreements (the “Voting Agreements”) with certain shareholders of Akari (the “Akari Shareholders”), and certain stockholders of Peak Bio (the “Peak Stockholders” and, together with the Akari Shareholders, the “Supporting Holders”). The Supporting Holders have agreed to, among other things, vote their shares in favor of the Merger Agreement and the Merger or the issuance of Akari Ordinary Shares in connection therewith, as applicable, in accordance with the recommendation of the respective boards of directors of Akari and Peak Bio. The Voting Agreements will terminate at the earliest to occur of (a) the Effective Time, (b) receipt of approval of the Supporting Holders, as applicable, and (c) such date and time as the Merger Agreement is validly terminated.

Fair Value Measurements

Fair Value Measurements	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4. Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents information about the Company’s financial liabilities measured at fair value on a re cu June 30, 2024 (In thousands) Total Level 1 Level 2 Level 3 Liabilities Warrant liability - Series A $ —  $ —  $ —  $ —  Warrant liability - Series B 755 —  —  755 Total liabilities $ 755 $ —  $ —  $ 755 December 31, 2023 (In thousands) Total Level 1 Level 2 Level 3 Liabilities Warrant liability - Series A $ 15 $ —  $ —  $ 15 Warrant liability - Series B 1,238 —  —  1,238 Total liabilities $ 1,253 $ —  $ —  $ 1,253 The Company’s Level 3 liabilities consist of the September 2022 Warrants, which were determined to be liability-classified instruments. There were no transfers between Level 1, Level 2, and Level 3 during the six months ended June 30, 2024 and 2023. Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis The following table summarizes the activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) during the six months ended June 30, 2024: Warrant Liability (In thousands) Series A Series B Total Balance, December 31, 2023 $ 15 $ 1,238 $ 1,253 Change in the fair value of liability (15 ) (483 ) (498 ) Balance, June 30, 2024 $ —  $ 755 $ 755 Assumptions Used in Determining Fair Value of Liability-Classified Warrants The fair value of the warrant liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of both the Series A Warrants and the Series B Warrants (each defined below) was determined using the Black-Scholes Option Pricing Model, which uses various assumptions, including (i) fair value of the Company’s ADSs, (ii) exercise price of the warrant, (iii) expected term of the warrant, (iv) expected volatility and (v) expected risk-free interest rate. Below are the assumptions used for the fair value calculations of the Series A Warrants and Series B Warrants (each defined below), as of June 30, 2024 and December 31, 2023: June 30, 2024 December 31, 2023 Series A Series B Series A Series B Stock (ADS) price $ 2.70 $ 2.70 $ 3.12 $ 3.12 Exercise price $ 17.00 $ 17.00 $ 17.00 $ 17.00 Expected term (in years) 0.2 5.2 0.7 5.7 Expected volatility 135.0 % 85.0 % 85.0 % 95.0 % Risk-free interest rate 5.5 % 4.3 % 5.1 % 3.9 % Expected dividend yield —  —  —  —	Note 3. Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis The following table presents information about the Company’s financial liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such values: December 31, 2023 (In thousands) Total Level 1 Level 2 Level 3 Liabilities Warrant liability - Series A $ 15 $ —  $ —  $ 15 Warrant liability - Series B 1,238 —  —  1,238 Total liabilities $ 1,253 $ —  $ —  $ 1,253 December 31, 2022 (In thousands) Total Level 1 Level 2 Level 3 Liabilities Warrant liability - Series A $ 1,812 $ —  $ —  $ 1,812 Warrant liability - Series B 6,040 —  —  6,040 Total liabilities $ 7,852 $ —  $ —  $ 7,852 The Company’s Level 3 liabilities consist of the September 2022 Warrants (defined below), which were determined to be liability-classified instruments. There were no transfers between Level 1, Level 2, and Level 3 during the years ended December 31, 2023 and 2022. Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis The following table summarizes the activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) during the years ended December 31, 2023 and 2022: Warrant Liability (In thousands) Series A Series B Total Balance, December 31, 2021 $ —  $ —  $ —  Issuance of warrants 5,285 9,513 14,798 Change in the fair value of liability (3,473 ) (3,473 ) (6,946 ) Balance, December 31, 2022 $ 1,812 $ 6,040 $ 7,852 Change in the fair value of liability (1,797 ) (4,802 ) (6,599 ) Balance, December 31, 2023 $ 15 $ 1,238 $ 1,253 Assumptions Used in Determining Fair Value of Liability-Classified Warrants The fair value of the warrant liability is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of both the Series A Warrants and the Series B Warrants (each defined below) was determined using the Black-Scholes Option Pricing Model, which uses various assumptions, including (i) fair value of the Company’s ADSs, (ii) exercise price of the warrant, (iii) expected term of the warrant, (iv) expected volatility and (v) expected risk-free interest rate. Below are the assumptions used for the fair value calculations of the Series A Warrants and Series B Warrants (each defined below), as of December 31, 2023 and 2022, adjusted, where applicable, to reflect the ADS Ratio Change for all periods presented, as more fully described in Note 1: December 31, 2023 December 31, 2022 Series A Series B Series A Series B Stock (ADS) price $ 3.12 $ 3.12 $ 9.40 $ 9.40 Exercise price $ 17.00 $ 17.00 $ 17.00 $ 17.00 Expected term (in years) 0.7 5.7 1.7 6.7 Expected volatility 85.0 % 95.0 % 80.0 % 120.0 % Risk-free interest rate 5.1 % 3.9 % 4.4 % 4.0 % Expected dividend yield —  —  —  —

Accrued Expenses

Accrued Expenses	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses	Note 5. Accrued Expenses Accrued expenses consisted of the following as of June 30, 2024 and December 31, 2023: ($ in thousands) June 30, December 31, Employee compensation and benefits $ 377 $ 187 External research and development expenses 446 635 Professional and consulting fees 363 669 Restructuring 458 —  Other 41 75 Total accrued expenses $ 1,685 $ 1,566 Accrued restructuring expenses of $0.5 million as of June 30, 2024 relate to one-time	Note 4. Accrued Expenses Accrued expenses consisted of the following as of December 31, 2023 and 2022: ($ in thousands) December 31, December 31, Employee compensation and benefits $ 187 $ 1,426 External research and development expenses 635 1,446 Professional and consulting fees 669 148 Other 75 128 Total accrued expenses $ 1,566 $ 3,148

Shareholders' (Deficit) Equity

Shareholders' (Deficit) Equity	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Shareholders' (Deficit) Equity	Note 6. Shareholders’ (Deficit) Equity Ordinary Shares On June 30, 2023, the Company’s shareholders approved an increase to the number of authorized ordinary shares, par value $0.0001 (the “Ordinary Shares”), the Company can issue by 35,000,000,000 ordinary shares in addition to the number of shares outstanding on June 30, 2023. Accordingly, as of June 30, 2024 and December 31, 2023, the Company was authorized to issue up to 45,122,321,523 ordinary shares. Currently, each ADS represents 2,000 Ordinary Shares (the “ADS Ratio”). All ADS and per ADS amounts in the accompanying condensed consolidated financial statements reflect the ADS Ratio. May 2024 Private Placement In May 2024, the Company entered into a definitive purchase agreement with certain investors, Dr. Prudo and Dr. Patel, pursuant to which the Company sold and issued in a private placement an aggregate of 4,029,754 ADSs, and Series C Warrants (the “Series C Warrants”) to purchase up to 4,029,754 ADS, at a per unit price of $1.885 per ADS and Series C Warrant for aggregate gross proceeds of approximately $7.6 million (the “May 2024 Private Placement”). The Series C Warrants have 3-year At close of the May 2024 Private Placement, the Company issued to Paulson Investment Company, LLC (“Paulson”), as placement agent for the May 2024 Private Placement, warrants to purchase 332,380 ADSs at an exercise price of $1.885 per ADS and a term expiring on May 31, 2029 (the “May 2024 Placement Agent Warrants”). The estimated fair value of the May 2024 Placement Agent Warrants on the issuance date was approximately $0.4 million. The Company determined that the Series C Warrants and May 2024 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the May 2024 Private Placement, each of the Series C Warrants and May 2024 Placement Agent Warrants were recorded as a component of additional paid-in March 2024 Private Placement In March 2024, the Company entered into a definitive purchase agreement with certain existing investors, pursuant to which the Company sold and issued in a private placement an aggregate of 1,320,614 ADSs at $1.48 per ADS, for aggregate gross proceeds of approximately $2.0 million (the “March 2024 Private Placement”). Net proceeds from the March 2024 Private Placement were approximately $1.7 million after deducting placement agent fees and other expenses. At close of the March 2024 Private Placement, the Company issued to Paulson, as placement agent for the March 2024 Private Placement, warrants to purchase 132,061 ADSs at an exercise price of $1.85 per ADS (representing 125% of the purchase price per ADS sold in the March 2024 Private Placement) and a term expiring on March 27, 2029 (the “March 2024 Placement Agent Warrants”). The estimated fair value of the March 2024 Placement Agent Warrants on the issuance date was approximately $0.2 million. The Company determined that the March 2024 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the March 2024 Private Placement, each of the March 2024 Placement Agent Warrants were recorded as a component of additional paid-in December 2023 Private Placement In December 2023, the Company entered into purchase agreements to sell, in a private placement, to existing investors, Dr. Ray Prudo and Dr. Patel, (the “December 2023 Private Placement”) an aggregate of 947,868 ADSs at $2.11 per ADS, for aggregate gross proceeds of approximately $2.0 million. Net proceeds from the December 2023 Private Placement were approximately $1.8 million after deducting placement agent fees and other expenses. September 2023 Private Placement In September 2023, the Company entered into purchase agreements to sell in a private placement to existing investors and directors, including Dr. Prudo and Ms. Rachelle Jacques, the Company’s then President and Chief Executive Officer (the “September 2023 Private Placement”) an aggregate of 551,816 ADSs at $3.30 per ADS, and pre-funded “Pre-Funded Pre-Funded Pre-Funded At close of the September 2023 Private Placement, the Company issued to Paulson, as placement agent for the September 2023 Private Placement, warrants to purchase 42,550 ADSs at an exercise price of $4.13 per ADS (representing 125% of the purchase price per ADS sold in the September 2023 Private Placement) and a term expiring on October 6, 2028 (the “October 2023 Placement Agent Warrants”). The estimated fair value of the October 2023 Placement Agent Warrants on the issuance date was approximately $0.1 million. The Company determined that the Pre-Funded Pre-Funded paid-in March 2023 Registered Direct Offering On March 31, 2023, the Company entered into securities purchase agreements with certain accredited and institutional investors, including Dr. Prudo (the “March Registered Direct Offering”) providing for the issuance of an aggregate of 1,333,333 ADSs in a registered direct offering at $3.00 per ADS, resulting in gross proceeds of approximately $4.0 million. Net proceeds from the March Registered Direct Offering were approximately $3.5 million after deducting placement agent fees and expenses. Warrants In connection with various financing transactions, the Company has issued warrants to purchase the Company’s ordinary shares represented by ADSs. The Company accounts for such warrants as equity instruments or liabilities, depending on the specific terms of the warrant agreement. See Note 2 for further details on accounting policies related to the Company’s warrants. The following table summarizes the Company’s outstanding warrants as of June 30, 2024 and December 31, 2023: Number of Warrant ADSs June 30, December 31, Weighted- Expiration Date Equity-classified Warrants 2019 Investor Warrants 59,211 59,211 $ 60.00 7/1/2024 2019 Placement Warrants —  8,881 $ 57.00 6/28/2024 2020 Investor Warrants 139,882 139,882 $ 44.00 Feb-Mar 2025 2020 Placement Warrants 22,481 22,481 $ 51.00 Feb-Mar July 2021 Placement Agent Warrants 19,919 19,919 $ 46.40 7/7/2026 December 2021 Investor Warrants 107,775 107,775 $ 33.00 1/4/2027 December 2021 Placement Agent Warrants 8,622 8,622 $ 35.00 12/29/2026 March 2022 Investor Warrants 186,020 186,020 $ 28.00 3/10/2027 March 2022 Placement Agent Warrants 14,882 14,882 $ 30.00 3/10/2027 October 2023 Investor Prefunded Warrants 48,387 48,387 $ 0.20 — October 2023 Placement Agent Warrants 42,550 42,550 $ 4.13 10/6/2028 March 2024 Placement Agent Warrants 132,061 —  $ 1.85 3/27/2029 May 2024 Investor Warrants 4,029,754 —  $ 1.77 May-Jun 2027 May 2024 Placement Agent Warrants 322,380 —  $ 1.89 5/31/2029 5,133,924 658,610 Liability-classified Warrants September 2022 Series A Investor Warrants 755,000 755,000 $ 17.00 9/14/2024 September 2022 Series B Investor Warrants 755,000 755,000 $ 17.00 9/14/2029 1,510,000 1,510,000 Total outstanding 6,643,924 2,168,610 The following table summarizes the Company’s warrants activity for the six months ended June 30, 2024: ($ in thousands, except per share data) Number of Weighted-Average Outstanding at December 31, 2023 2,168,610 $ 21.97 Issued 4,484,195 1.78 Exercised —  —  Expired (8,881 ) 57.00 Outstanding at June 30, 2024 6,643,924 $ 8.30 Capital Redemption Reserve In December 2020, for the purpose of changing the nominal value of the Company’s ordinary shares from £0.01 to $0.0001 the Company issued 3,847,331,913 deferred shares (the “Deferred Shares”) of $0.01315. The Deferred Shares were created for technical reasons of company law and did not increase the aggregate value of share capital. Also in December 2020, the Deferred Shares were purchased by the Company in accordance with their terms of issue for aggregate consideration of $0.01 and immediately cancelled. The aggregate nominal value at cancellation was $50.6 million. Amounts transferred from share capital on the redemption of the Deferred Shares of $50.6 million, along with the resulting foreign currency effect of the redenomination of Company ordinary shares of $1.6 million, are classified as “capital redemption reserve” within the Company’s condensed consolidated balance sheets and condensed statements of shareholders’ (deficit) equity.	Note 5. Shareholders’ (Deficit) Equity Ordinary Shares On June 30, 2023, the Company’s shareholders approved an increase to the number of authorized ordinary shares the Company can issue by 35,000,000,000 ordinary shares in addition to the number of shares outstanding on June 30, 2023. Accordingly, following June 30, 2023 and as of December 31, 2023, the Company was authorized to issue up to 45,122,321,523 ordinary shares. As of December 31, 2022, the Company was authorized to issue up to 15,000,000,000 ordinary shares. December 2023 Private Placement In December 2023, the Company entered into purchase agreements to sell in a private placement to existing investors, Dr. Prudo, the Company’s Chairman, and Dr. Patel, director, (the “December 2023 Private Placement”) an aggregate of 947,868 ADSs at $2.11 per ADS, for aggregate gross proceeds of approximately $2.0 million. Net proceeds from the December 2023 Private Placement was approximately $1.8 million after deducting placement agent fees and other expenses. September 2023 Private Placement In September 2023, the Company entered into purchase agreements to sell in a private placement to existing investors, including Dr. Ray Prudo, the Company’s Chairman, and Ms. Rachelle Jacques, the Company’s President and CEO (the “September 2023 Private Placement”) an aggregate of 551,816 ADSs at $3.30 per ADS, and pre-funded “Pre-Funded Pre-Funded Pre-Funded At close of the September 2023 Private Placement, the Company issued to Paulson Investment Company, LLC (“Paulson”), as placement agent for the September 2023 Private Placement, warrants to purchase 42,550 ADSs at an exercise price of $4.13 per ADS (representing 125% of the price per ADS in the September 2023 Private Placement) and a term expiring on October 6, 2028 (the “October 2023 Placement Agent Warrants”). The estimated fair value of the October 2023 Placement Agent Warrants on the issuance date was approximately $0.1 million. The Company determined that the Pre-Funded Pre-Funded paid-in March 2023 Registered Direct Offering On March 31, 2023, the Company entered into securities purchase agreements with certain accredited and institutional investors, including Dr. Ray Prudo, the Company’s Chairman, (the “March Registered Direct Offering”) providing for the issuance of an aggregate of 1,333,333 ADSs in a registered direct offering at $3.00 per ADS, resulting in gross proceeds of approximately $4.0 million. Net proceeds from the March Registered Direct Offering was approximately $3.5 million after deducting placement agent fees and expenses. September 2022 Registered Direct Offering On September 14, 2022, the Company sold to certain accredited and institutional investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company’s Chairman, an aggregate of 755,000 ADSs in a registered direct offering (“September 2022 Registered Direct Offering”) at $17.00 per ADS for aggregate gross proceeds of approximately $12.8 million. In connection with the sale of the ADSs in the September 2022 Registered Direct Offering, the Company issued to the investors registered Series A warrants (“Series A Warrants”) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS and registered Series B warrants (“Series B Warrants”) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS (collectively, the “September 2022 Warrants”). The Company determined that the September 2022 Warrants are not indexed to the Company’s own stock in the manner contemplated by ASC 815-40-15, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock non-operating The Company measures the fair value of the September 2022 warrants at the end of each reporting period and recognizes changes in the fair value of the September 2022 warrants as a non-operating March 2022 Registered Direct Offering On March 10, 2022, the Company sold to certain accredited and institutional investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company’s Chairman, an aggregate of 372,042 ADSs in a registered direct offering (“March 2022 Registered Direct Offering”) at $24.00 per ADS for aggregate gross proceeds of approximately $8.9 million. In connection with the sale of the ADSs in the March 2022 Registered Direct Offering, the Company issued to the investors registered warrants to purchase an aggregate of 186,020 ADSs at $28.00 per ADS (the “March 2022 Investor Warrants”). The March 2022 Investor Warrants are immediately exercisable and will expire five years from issuance, subject to adjustment as set forth therein. In connection with the offering, the Company paid Paulson, as placement agent, approximately $0.8 million in placement agent fees and expenses and issued registered warrants to Paulson to purchase an aggregate of 14,882 ADS (the “March 2022 Placement Agent Warrants”) on the same terms as the March 2022 Investor Warrants, except that the March 2022 Placement Agent Warrants are exercisable at $30.00 per ADS. The Company determined that the March 2022 Investor Warrants and March 2022 Placement Agent Warrants met all of the criteria for equity classification. Accordingly, upon closing of the March 2022 Registered Direct Offering, each of the March 2022 Investor Warrants and March 2022 Placement Agent Warrants were recorded as a component of additional paid-in 2021 Registered Offering In December 2021, The Company sold to certain accredited and institutional investors, led by existing investors, including Dr. Ray Prudo, the Company’s Chairman, an aggregate of 215,550 ADSs in a registered direct offering (the “2021 Registered Offering”) at 28.00 per ADS for aggregate gross proceeds of approximately $6.0 million, which closed on January 5, 2022. As of December 31, 2021, the Company had received approximately $1.1 million of gross proceeds which were classified as current liabilities on its balance sheet until closing in January 2022, which at that time the remaining $4.9 million in gross proceeds were received. In connection with the offering, the Company issued to the investors and Paulson, as placement agent for the 2021 Registered Offering, registered warrants to purchase 107,775 ADSs at $33.00 per ADS and 8,622 ADSs at $35.00 per ADS, respectively. Net proceeds after deducting placement agent fees and other expenses were approximately $5.4 million, of which $4.3 million was received in 2022. Warrants In connection with various financing transactions, the Company has issued warrants to purchase the Company’s ordinary shares represented by ADSs. The Company accounts for such warrants as equity instruments or liabilities, depending on the specific terms of the warrant agreement. See Note 2 for further details on accounting policies related to the Company’s warrants. The following table summarizes the Company’s outstanding warrants as of December 31, 2023 and 2022: Number of Warrant ADSs December 31, December 31, Weighted- Expiration Date Equity-classified Warrants 2019 Investor Warrants 59,211 59,211 $ 60.00 7/1/2024 2019 Placement Warrants 8,881 8,881 $ 57.00 6/28/2024 2020 Investor Warrants 139,882 139,882 $ 44.00 Feb-Mar 2025 2020 Placement Warrants 22,481 22,481 $ 51.00 Feb-Mar July 2021 Placement Agent Warrants 19,919 19,919 $ 46.40 7/7/2026 December 2021 Investor Warrants 107,775 107,775 $ 33.00 1/4/2027 December 2021 Placement Agent Warrants 8,622 8,622 $ 35.00 12/29/2026 March 2022 Investor Warrants 186,020 186,020 $ 28.00 3/10/2027 March 2022 Placement Agent Warrants 14,882 14,882 $ 30.00 3/10/2027 October 2023 Investor Prefunded Warrants 48,387 —  $ 0.20 — October 2023 Placement Agent Warrants 42,550 —  $ 4.13 10/6/2028 658,610 567,673 Liability-classified Warrants September 2022 Series A Investor Warrants 755,000 755,000 $ 17.00 9/14/2024 September 2022 Series B Investor Warrants 755,000 755,000 $ 17.00 9/14/2029 1,510,000 1,510,000 Total outstanding 2,168,610 2,077,673 The following table summarizes the Company’s warrants activity for the year ended December 31, 2023: ($ in thousands, except per share data) Number of Weighted-Average Outstanding at December 31, 2022 2,077,673 $ 22.85 Issued 90,937 2.04 Exercised —  —  Expired —  —  Outstanding at December 31, 2023 2,168,610 $ 21.97

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 7. Share-Based Compensation 2023 Equity Incentive Plan On June 30, 2023, the Company’s shareholders approved the 2023 Equity Incentive Plan (the “2023 Plan”), which provides for the grant of stock options, both incentive stock options and nonqualified stock options, stock, with and without vesting restrictions, restricted stock units (“RSUs”) and stock appreciation rights, to be granted to employees, directors and consultants. The Company is permitted to issue up to 980,000,000 ordinary shares under the 2023 Plan, plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the 2014 Equity Incentive Plan (the “2014 Plan”), to the extent such awards are forfeited, cancelled, or expire unexercised. As of June 30, 2024, the Company had 318,823,915 ordinary shares underlying outstanding equity awards under the 2023 Plan, consisting of stock options and RSUs, and 724,581,522 ordinary shares remained available for future grants under the 2023 Plan. The 2023 and 2014 Plans provide that they be administered by the compensation committee of the board of directors. The exercise price for stock option awards may not be less than 100% of the fair market value of the Company’s ordinary shares on the date of grant and the term of awards may not be greater than ten years. The Company determines the fair value of its ordinary shares based on the quoted market price of its ADSs. Vesting periods are determined at the discretion of the compensation committee. Awards granted to employees typically vest over two four 2014 Equity Incentive Plan Under the 2014 Plan the Company was authorized to grant stock options, RSUs and other awards, to employees, members of the board of directors and consultants. Upon effectiveness of the 2023 Plan no further awards were available to be issued under the 2014 Plan. As of June 30, 2024, the Company had 284,934,688 ordinary shares underlying outstanding equity awards under the 2014 Plan, consisting of stock options. Stock Options The following is a summary of the Company’s stock option activity under the 2014 Plan and the 2023 Plan for the six months ended June 30, 2024: ($ in thousands, except share and per share data) Stock Options Weighted- Weighted- Aggregate Outstanding at December 31, 2023 651,237,400 $ 0.01 8.5 $ —  Granted 25,000,000 —  Exercised —  —  Forfeited (299,802,712 ) 0.01 Expired (24,500,000 ) 0.02 Outstanding at June 30, 2024 (1) 351,934,688 $ 0.01 4.6 $ —  Exercisable at June 30, 2024 263,101,355 $ 0.01 3.2 $ —  (1) Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company’s ordinary shares for those options that had exercise prices lower than the fair value of the Company’s ordinary shares. The weighted-average grant-date fair value per share of options granted during each of the six months ended June 30, 2024 and 2023 was less than $0.01. Option Valuation The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis: 2024 2023 Expected volatility 98.0 % 99.3 % Risk-free interest rate 4.3 % 3.8 % Expected dividend yield —  —  Expected term (in years) 5.5 6.0 Restricted Stock Units The 2014 Plan provided, and the 2023 Plan provides, for the award of RSUs. RSUs are granted to employees that are subject to time-based vesting conditions that lapse between one year and four years from date of grant, assuming continued employment. Compensation cost for time-based RSUs, which vest only on continued service, is recognized on a straight-line basis over the requisite service period based on the grant date fair of the RSUs, which is derived from the closing price of the Company’s ADSs on the date of grant. The following table summarizes the Company’s RSU activity for the six months ended June 30, 2024: Time-based Awards ($ in thousands, except per share data) Number of Weighted-Average Nonvested shares at December 31, 2023 385,954,925 $ 0.00 Granted 731,393,807 0.00 Forfeited (482,249,417 ) 0.00 Vested (383,275,400 ) 0.00 Nonvested shares at June 30, 2024 251,823,915 $ 0.00 The fair value of time-based RSUs that vested during the six months ended June 30, 2024 and 2023 was approximately $0.5 million and $0.1 million, respectively. As of June 30, 2024, 290,937,175 ordinary shares underlying vested time-based RSUs, which have been included in the condensed consolidated statement of shareholders’ (deficit) equity, were pending issuance. Share-Based Compensation Expense The Company classifies share-based compensation expense in the statement of operations in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. Total share-based compensation expense attributable to share-based payments made to employees, consultants and directors included in operating expenses in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023, was as follows: Three Months Ended Six Months Ended ($ in thousands) 2024 2023 2024 2023 Research and development $ 13 $ 32 $ 56 $ 63 General and administrative 147 244 400 478 Restructuring and other costs 285 —  285 —  Total share-based compensation expense $ 445 $ 276 $ 741 $ 541 During the three and six months ended June 30, 2024, 276,000,000 ordinary shares underlying unvested time-based RSUs held by a former executive upon termination of employment were accelerated, resulting in additional stock-based compensation expense of $0.3 million. As of June 30, 2024, total unrecognized compensation cost related to unvested stock options and time-based RSUs was $0.2 million and $0.2 million, respectively. The Company expects total unrecognized compensation costs related to unvested stock options and RSUs to be recognized over a weighted average period of 1.8 and 1.7 years, respectively.	Note 6. Stock-Based Compensation 2023 Equity Incentive Plan On June 30, 2023, the Company’s shareholders approved the 2023 Equity Incentive Plan (the “2023 Plan”), which provides for the grant of stock options, both incentive stock options and nonqualified stock options, stock, with and without vesting restrictions, restricted stock units and stock appreciation rights, to be granted to employees, directors and consultants. The Company is permitted to grant up to 980,000,000 ordinary share incentive awards under the 2023 Plan. All outstanding ordinary shares under the 2014 Equity Incentive Plan (the “2014 Plan”) relating to stock options and restricted stock units may be issued under the 2023 Plan if such awards are forfeited, cancelled or expire unexercised. As of June 30, 2023, the Company had 855,637,300 ordinary shares underlying outstanding equity awards under the 2014 Plan, consisting of stock options and restricted stock units. Accordingly, the total number of ordinary shares that may ultimately be issued under rights granted under the 2023 Plan, including shares subject to outstanding grants under the 2014 Plan, shall not exceed 1,835,637,300 ordinary shares. In addition, if an award issued under the 2023 Plan is terminated or results in any shares not being issued, the unissued or reacquired shares shall again be available for issuance under the 2023 Plan. As of December 31, 2023, the Company had 247,798,825 ordinary shares underlying outstanding equity awards under the 2023 Plan and 765,819,200 ordinary shares were available for future issuance under the 2023 Plan. The 2023 and 2014 Plans provide that they be administered by the compensation committee of the board of directors. The exercise price for stock option awards may not be less than 100% of the fair market value of the Company’s ordinary shares on the date of grant and the term of awards may not be greater than ten years. The Company determines the fair value of its ordinary shares based on the quoted market price of its ADSs. Vesting periods are determined at the discretion of the compensation committee. Awards granted to employees typically vest over two 2014 Equity Incentive Plan Under the 2014 Plan the Company was authorized to grant stock options, restricted stock units and other awards, to employees, members of the board of directors and consultants. Upon effectiveness of the 2023 Plan no further awards were available to be issued under the 2014 Plan. As of December 31, 2023, the Company had 789,393,500 ordinary shares underlying outstanding equity awards under the 2014 Plan, consisting of stock options and restricted stock units. Stock Options The following is a summary of the Company’s stock option activity under the 2014 Plan and the 2023 Plan for the year ended December 31, 2023: ($ in thousands, except share and per share data) Stock Weighted- Weighted- Aggregate Outstanding at December 31, 2022 513,673,885 $ 0.02 8.7 $ —  Granted 223,690,700 0.00 Exercised —  —  Forfeited (27,127,185 ) 0.03 Expired (59,000,000 ) 0.04 Outstanding at December 31, 2023 (1) 651,237,400 $ 0.01 8.5 $ —  Exercisable at December 31, 2023 212,510,100 $ 0.02 7.6 $ —  (1) Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. The weighted-average grant-date fair value per share of options granted during each of the years ended December 31, 2023 and 2022 was less than $0.01. Option Valuation The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis: 2023 2022 Expected volatility 98.7 % 76.1 % Risk-free interest rate 3.8 % 3.1 % Expected dividend yield —  —  Expected term (in years) 6.0 6.1 Restricted Stock Units The 2014 Plan provided, and the 2023 Plan provides, for the award of restricted stock units (“RSUs”). RSUs are granted to employees that are subject to time-based vesting conditions that lapse between one year and four years from date of grant, assuming continued employment. Compensation cost for time-based RSUs, which vest only on continued service, is recognized on a straight-line basis over the requisite service period based on the grant date fair of the RSU’s, which is derived from the closing price of the Company’s ADS’s on the date of grant. The following table summarizes the Company’s restricted stock activity for the year ended December 31, 2023: Time-based Awards ($ in thousands, except per share data) Number of Shares Weighted-Average Nonvested shares at December 31, 2022 21,475,400 $ 0.01 Granted 407,843,000 0.00 Forfeited —  —  Vested (43,363,475 ) 0.01 Nonvested shares at December 31, 2023 385,954,925 $ 0.00 The fair value of time-based RSUs that vested during the year ended December 31, 2023 was approximately $0.2 million. No time-based RSUs vested during the year ended December 31, 2022. As of December 31, 2023, 28,151,775 ordinary shares underlying vested time-based RSUs, which have been included in the consolidated statement of shareholders’ equity, were pending issuance. Stock-Based Compensation Expense The Company classifies stock-based compensation expense in the statement of operations in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. Total stock-based compensation expense attributable to stock-based payments made to employees, consultants and directors included in operating expenses in the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022, was as follows: Year Ended December 31, ($ in thousands) 2023 2022 Research and development $ 153 $ 120 General and administrative 997 615 Total stock-based compensation expense $ 1,150 $ 735 As of December 31, 2023, total unrecognized compensation cost related to unvested stock options and time-based RSUs was $1.7 million and $0.6 million, respectively, each of which is expected to be recognized over a weighted average period of 2.4 years.

Related Party Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 8. Related Party Transactions The Doctors Laboratory The Company leases office space for its U.K. headquarters in London from The Doctors Laboratory (“TDL”) and has incurred expenses of less than $0.1 million plus VAT during each of the three and six months ended June 30, 2024 and 2023. David Byrne, a former non-employee non-Executive The Company received certain laboratory testing services for its clinical trials provided by TDL, including certain administrative services, and incurred expenses of less than $0.1 million during each of the three and six months ended June 30, 2024 and 2023. The Company recorded payable balances owed to TDL of less than $0.1 million as of June 30, 2024 and December 31, 2023. Interim CEO Agreement On May 31, 2024, the Company and Dr. Patel entered into an Interim Chief Executive Officer Agreement, effective as of May 1, 2024 (the “Interim CEO Agreement”). Pursuant to the Interim CEO Agreement, Dr. Patel serves as the Company’s Interim President and Chief Executive Officer as an independent contractor on an at-will During the three and six months ended June 30, 2024, the Company granted 91,396,000 fully vested ordinary shares to Dr. Patel and recognized approximately $0.1 million in compensation costs pursuant to the Interim CEO Agreement. As of June 30, 2024, the 91,396,000 ordinary shares granted to Dr. Patel, which have been included in the condensed consolidated statement of shareholders’ (deficit) equity, were pending issuance.	Note 7. Related Party Transactions The Doctors Laboratory The Company leases office space for its U.K. headquarters in London from non-employee non-Executive The Company received certain laboratory testing services for its clinical trials provided by TDL, including certain administrative services, and incurred expenses of approximately $0.1 million during each of the years ended December 31, 2023 and 2022. The Company recorded payable balances owed to TDL of less than $0.1 million as of December 31, 2023 and 2022. Other A non-employee

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Leases The Company is currently party to a short-term lease for its U.S headquarters, which currently expires in November 2024, and a short-term lease with TDL for its London offices, which currently expires in July 2025. The Company is not party to any material lease agreements. For each of the three months ended June 30, 2024 and 2023, the Company incurred lease costs of less than $0.1 million. For the six months ended June 30, 2024 and 2023, the Company incurred leases costs of approximately $0.2 million and $0.1 million, respectively. Employee Benefit Plans The Company adopted an employee benefit plan under Section 401(k) of the Internal Revenue Code for its U.S.-based employees. The plan allows employees to make contributions up to a specified percentage of their compensation. Under the plan, the Company matches 100% of employees’ contributions up to 5% of the annual eligible compensation contributed by each employee, subject to Internal Revenue Code limitations. The Company also adopted a defined contribution pension scheme which allows for U.K. employees to make contributions and provides U.K. employees with a Company contribution of 10% of compensation, subject to U.K. law. During each of the three and six months ended June 30, 2024 and 2023, the Company charged less than $0.1 million to operating expenses related to the Company’s contributions to employee benefit plans.	Note 8. Commitments and Contingencies Leases The Company currently leases office space for its U.S headquarters on a month-to-month For each of the years ended December 31, 2023 and 2022, the Company incurred rent expense of approximately $0.2 million. Employee Benefit Plans The Company adopted an employee benefit plan under Section 401(k) of the Internal Revenue Code for its U.S.-based employees. The plan allows employees to make contributions up to a specified percentage of their compensation. Under the plan, the Company matches 100% of employees’ contributions up to 5% of annual eligible compensation contributed by each employee, subject to Internal Revenue Code limitations. The Company also adopted a defined contribution pension scheme which allows for U.K. employees to make contributions and provides U.K. employees with a Company contribution of 10% of compensation, subject to U.K. law. During each of the years ended December 31, 2023 and 2022, the Company charged approximately $0.2 million to operating expenses related to the Company’s contributions to employee benefit plans.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. Income Taxes The components of net loss before income tax are as follows: Year Ended December 31, 2023 2022 Domestic (UK) $ (10,267 ) $ (18,018 ) Foreign 259 270 Net loss before income tax $ (10,008 ) $ (17,748 ) The components of income tax expense are as follows: Year Ended December 31, 2023 2022 Current income taxes Domestic (UK) $ —  $ —  U.S. —  —  Foreign —  —  Deferred income taxes Domestic (UK) —  —  Foreign —  —  Income tax expense $ —  $ —  As of December 31, 2023 and 2022 the tax effects of temporary differences and carryforwards that give rise to significant portions of the Company’s deferred tax assets were as follows: (in thousands) December 31, December 31, Deferred tax assets Stock-based compensation $ 480 $ 955 PP&E and other accrued liabilities 899 642 Intangibles 780 1,659 Warrant revaluation (2,895 ) (947 ) Tax loss carry forward 42,978 32,307 Total deferred tax assets 42,242 34,616 Valuation allowance (42,242 ) (34,616 ) Net deferred tax assets $ —  $ —  Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax assets relating to the loss carryforwards and other temporary differences will not be realized in the foreseeable future. Therefore, the Company provided a full valuation allowance to reduce the deferred tax assets as of December 31, 2023 and 2022. The United Kingdom’s Finance Act 2021, which was enacted on June 10, 2021, maintained the corporate income tax rate at 19% up until the tax year commencing April 1, 2023, at which point the rate rose to 25%. As of December 31, 2023, the Company used a 25% and 21% tax rate in respect of the measurement of deferred taxes existing in the U.K. and the U.S., respectively, which reflects the currently enacted tax rates and the anticipated timing of the reversing of the deferred tax balances. The following is a reconciliation of income tax expense computed at the UK statutory rate (2023: 23.5% (pro-rated), Year Ended December 31, 2023 2022 Net loss before income tax $ (10,008 ) $ (17,748 ) Statutory rate 23.50 % 19.00 % Expected income tax recovery (2,352 ) (3,372 ) Impact on income tax expense/recovery from Change in valuation allowance 7,617 4,327 Permanent differences 4 408 U.S. state taxes (net of FBOS) 1,394 (1,114 ) Tax rate difference in foreign jurisdictions (974 ) (248 ) Change of tax rate due to U.S. tax reform —  4 Change in equity compensation 123 752 Change in operating losses (94 ) (133 ) Change of tax rate from prior year (6,635 ) (624 ) Deferred tax adjustments 760 —  Non-deductible 157 —  Income tax expense $ —  $ —  At December 31, 2023 and 2022, there were no known domestic or foreign uncertain tax positions and the Company has not identified any tax positions for which it is reasonably possible that a significant change will occur during the next 12 months. The Company’s position is to record penalties and interest on any uncertain tax position, if any, to general and administrative expense in the consolidated statements of operations. At December 31, 2023, the Company had cumulative UK, US federal, various US state, and Switzerland net operating loss carryforwards (“NOLs”) of approximately $125.2 million, $33.5 million, $60.3 million, and less than $0.1 million, respectively, available to reduce UK, US federal, US state and Switzerland taxable income, respectively. The UK NOLs do not expire. Of the $33.5 million of US federal NOLs, $27.7 million have an unlimited carryforward and the remaining NOLs are subject to expiration through 2037. Of the $60.3 million of US state NOLs, $29.2 million have an unlimited carryforward and the remaining NOLs are subject to expiration through 2043. In general, an ownership change, as defined by Section 382 of the Internal Revenue Code, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. In the second quarter of 2023, the Company conducted a study to assess whether a change of control has occurred. The Company concluded that it had experienced a change of control, as defined by Section 382, and utilization of certain net operating loss carryforwards would be subject to an annual limitation under Section 382. The Company determined that the limitation was immaterial to its consolidated financial statements. As no study has been completed subsequent to the second quarter of 2023, additional ownership change limitations may result from ownership changes that have occurred, or may occur in the future. Research and development credits The Company carries out extensive research and development activities and may benefit from the UK research and development tax relief regime, whereby the Company can receive an enhanced UK tax deduction on its research and development activities. Qualifying expenditures comprise of chemistry and manufacturing consumables, employment costs for research staff, clinical trials management, and other subcontracted research expenditures. Where the Company is loss making for the period it can elect to surrender taxable losses for a refundable tax credit. The losses available to surrender are equal to the lower of the sum of the research and development qualifying expenditure and enhanced tax deduction and the Company’s taxable losses for the period with the tax credit for December 31, 2023 available at a rate of 14.5%. The credit therefore gives a cash flow advantage to Company at a lower rate than would be available if the enhanced losses were carried forward and relieved against future taxable profits. The Company accounts for research and development tax credits at the time its realization becomes probable (Note 2). Due to the uncertainty of the approval of these tax credit claims and the potential that an election for a tax credit in the form of cash is not made, the Company did not record a receivable for the 2023 tax year at December 31, 2023.

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Subsequent Events
Subsequent Events	Note 10. Subsequent Events The Company considers events or transactions that oc cur a	Note 10. Subsequent Events The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. In some instances, such subsequent events may require retroactive adjustment to information reported at the balance sheet date. March 2024 Private Placement In March 2024, the Company entered into a definitive purchase agreement with certain existing investors, pursuant to which the Company sold and issued in a private placement an aggregate of 1,320,614 ADSs at $1.48 per ADS, for aggregate gross proceeds of approximately $2.0 million. Net proceeds from the March 2024 Private Placement was approximately $1.7 million after deducting placement agent fees and other expenses. Agreement and Plan of Merger On March 4, 2024, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Peak Bio, Inc. (“Peak Bio”) and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari (“Merger Sub”), pursuant to which, upon the terms and subject to the conditions thereof, Merger Sub will be merged with and into Peak Bio (the “Merger”), with Peak Bio surviving the Merger as a wholly-owned subsidiary of Akari. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the effective time of the Merger (the “Effective Time”), each issued and outstanding share of Peak Bio common stock, par value $0.0001 per share (the “Peak Common Stock”) (other than (x) shares of Peak Common Stock held by Peak Bio as treasury stock, or shares of Peak Common Stock owned by Akari, Merger Sub or any direct or indirect wholly-owned subsidiaries of Akari and (y) Dissenting Shares (as defined in the Merger Agreement), will be converted into the right to receive the Company’s ADSs representing a number of Akari ordinary shares, par value $0.0001 per share (the “Akari Ordinary Shares”) equal to an exchange ratio calculated in accordance with the Merger Agreement (the “Exchange Ratio”), each such share duly and validly issued against the deposit of the requisite number of Akari Ordinary Shares in accordance with the Deposit Agreement (as defined in the Merger Agreement). The Exchange Ratio will be calculated such that the total number of shares of Akari ADSs to be issued as merger consideration for the Peak Common Stock will be expected to be, upon issuance, approximately 50% of the outstanding shares of Akari ADSs (provided, certain adjustments to this ratio will be made in respect of the net cash, as determined in accordance with the Merger Agreement, of each of Akari and Peak Bio at the close of business one business day prior to the anticipated consummation of the Merger). The Merger Agreement provides that, under certain circumstances, additional Akari ADSs may be issued to the holders of shares of Peak Common Stock following the consummation of the Merger equal to an exchange ratio calculated in accordance with the Merger Agreement (the “Additional Exchange Ratio”). The board of directors of each of Akari and Peak has unanimously approved the Merger Agreement and the transactions contemplated thereby. Consummation of the Merger is subject to various conditions, including, among others, (i) approval of the Merger Agreement and Merger by Peak Bio stockholders, (ii) Akari’s shareholders authorizing Akari’s board of directors to allot all Akari ordinary shares to be issued in connection with the Merger (to be represented by Akari ADSs), (iii) the absence of any law or order prohibiting consummation of the Merger, (iv) Akari’s Registration Statement on Form S-4 Either Akari or Peak Bio may terminate the Merger Agreement under certain circumstances, including if (i) the Merger is not completed by September 4, 2024, (ii) the other party’s board of directors withdraws, modifies or qualifies its recommendation in favor of the transactions contemplated by the Merger Agreement or approves or recommends an alternative transaction or (iii) Akari’s or Peak Bio’s board of directors, as applicable, resolves to enter into a definitive agreement with respect to a superior proposal prior to obtaining approval of the Akari ADS issuance or Merger, as applicable, from Akari’s shareholders or Peak Bio’s stockholders, as applicable. The Merger Agreement also provides that under certain specified circumstances of termination described in the Merger Agreement, Akari or Peak Bio, as applicable, will be required to pay a termination fee equal to $300,000 and reimburse the other party for expenses related to the transaction up to $1.5 million. Concurrently with the Merger Agreement, Akari and Peak Bio entered into voting and support agreements (the “Voting Agreements”) with certain shareholders of Akari (the “Akari Shareholders”), and certain stockholders of Peak Bio (the “Peak Stockholders” and, together with the Akari Shareholders, the “Supporting Holders”). The Supporting Holders have agreed to, among other things, vote their shares in favor of the Merger Agreement and the Merger or the issuance of Akari Ordinary Shares in connection therewith, as applicable, in accordance with the recommendation of the respective boards of directors of Akari and Peak Bio. As of March 1, 2024, the Akari Shareholders beneficially owned an aggregate of approximately 39.51% of the outstanding Akari Ordinary Shares. As of March 1, 2024, the Peak Stockholders beneficially owned an aggregate of approximately 39.3% of the outstanding shares of Peak Common Stock. The Voting Agreements will terminate at the earliest to occur of (a) the Effective Time, (b) receipt of approval of the Supporting Holders, as applicable, and (c) such date and time as the Merger Agreement is validly terminated.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation 10-K,	Basis of presentation
Principles of Consolidation	Principles of consolidation –	Principles of consolidation –
Foreign Currency	Foreign currency – The reporting currency of the Company is U.S. dollars. The financial statements of certain of the Company’s foreign subsidiaries are measured using their local currency as the functional currency. The Company translates its non-U.S.	Foreign currency – The reporting currency of the Company is U.S. dollars. The Company translates its non-U.S.
Use of Estimates	Use of estimates –	Use of estimates –
Segments		Segments
Concentration of Credit Risk	Concentration of credit risk –	Concentration of credit risk –
Fair Value Measurements	Fair value measurements Fair Value Measurements and Disclosures • Level 1 • Level 2 • Level 3 Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. The fair value hierarchy also requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company’s cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The Company’s liability-classified warrants are recorded at their estimated fair value. See Note 4.	Fair value measurements Fair Value Measurements and Disclosures • Level 1 • Level 2 • Level 3 Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. The fair value hierarchy also requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company’s cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. The Company’s liability-classified warrants are recorded at their estimated fair value. See Note 3.
Cash	Cash –	Cash –
Prepaid Expenses	Prepaid expenses –	Prepaid expenses –
Other Current Assets	Other current assets	Other current assets
Patent Acquisition Costs	Patent acquisition costs	Patent acquisition costs
Accrued Expenses	Accrued expenses pre-clinical	Accrued expenses pre-clinical
Convertible Notes	Convertible Notes The Company accounts for convertible promissory notes in accordance with ASC Topic 470-20, Debt with Conversion and Other Options 470-20”)
Warrant Liability	Warrant Liability Distinguishing Liabilities from Equity Derivatives and Hedging paid-in In connection with the sale of the ADSs in the September 2022 Registered Direct Offering, the Company issued to the investors registered Series A warrants (“Series A Warrants”) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS and registered Series B warrants (“Series B Warrants”) to purchase an aggregate of 755,000 ADSs at $17.00 per ADS (collectively, the “September 2022 Warrants”).The Company determined that the September 2022 Warrants are not indexed to the Company’s own stock in the manner contemplated by ASC 815-40-15, Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock	Warrant Liability Distinguishing Liabilities from Equity Derivatives and Hedging paid-in
Other Current Liabilities	Other Current Liabilities
Research and Development Expenses	Research and development expenses – Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven cash flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company’s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the condensed consolidated statements of operations and comprehensive loss.	Research and development expenses – Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple contract research organizations and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven cash flows. There may be instances in which payments made to the Company’s vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical study milestones. In amortizing or accruing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company’s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. The Company accounts for research and development tax credits at the time its realization becomes probable as a credit to research and development expenses in the consolidated statements of operations and comprehensive loss.
Merger-Related Costs	Merger-Related Costs –
Restructuring and Other Costs	Restructuring and Other Costs – reduction-in-force HSCT-TMA reduction-in-force reduction-in-force, HSCT-TMA non-cash As of June 30, 2024, of the $1.6 million total restructuring-related charges incurred, $0.5 million was unpaid and included in accrued expenses in the accompanying condensed consolidated balance sheet. See Note 5. The Company expects these costs to be payable through the fourth quarter of 2024.
Share-Based Compensation	Share-based compensation expense – non-employees The fair value of each restricted ordinary share award is determined on the date of grant based on the fair value of the Company’s ordinary shares on that same date. The fair value of each share option grant is determined on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends. See Note 7. The Company estimates stock price volatility based on the Company’s historical stock price performance over a period of time that matches the expected term of the stock options. The expected term of the Company’s options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.	Stock-based compensation expense – non-employees The fair value of each restricted ordinary share award is determined on the date of grant based on the fair value of the Company’s ordinary shares on that same date. The fair value of each share option grant is determined on the date of grant using the Black-Scholes option pricing model, which requires inputs based on certain assumptions, including the expected stock price volatility, the expected term of the award, the risk-free interest rate, and expected dividends (See Note 6). Beginning on January 1, 2023, the Company began using its historical stock price volatility to determine the volatility assumption to be used in its Black-Scholes option pricing model. Prior to January 1, 2023, the Company estimated its expected stock price volatility based on the historical volatility of publicly traded peer companies. The expected term of the Company’s options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future.
Leases	Leases – Leases right-of-use	Leases – Leases right-of-use
Income Taxes	Income taxes Interim Reporting Income Taxes year-to-date	Income taxes The Company follows the provisions of ASC 740 “ Accounting for Uncertainty in Income Taxes de-recognition, Accounting for Uncertainty in Income Taxes “more-likely-than-not”
Comprehensive Income (Loss)		Comprehensive Income (Loss) non-owner
Net loss per share	Net loss per share pre-funded The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: As of June 30, 2024 2023 Stock options 351,934,688 680,112,400 Restricted stock units 251,823,915 418,580,700 Warrants 13,191,074,600 4,155,347,500 Convertible notes 1,257,860,000 —  Total 15,052,693,203 5,254,040,600	Net loss per share pre-funded For periods in which the Company has reported net losses, diluted net loss per ordinary share is the same as basic net loss per ordinary share, since dilutive ordinary shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss for each of the years ended December 31, 2023 and 2022. The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: Year Ended December 31, 2023 2022 Stock options 651,237,400 513,673,885 Restricted stock units 385,954,925 21,475,400 Warrants 4,240,447,500 4,155,347,500 Total 5,277,639,825 4,690,496,785
New Accounting Pronouncements	New Accounting Pronouncements Recently Issued (Not Yet Adopted) Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures	New Accounting Pronouncements Recently Issued (Not Yet Adopted) Accounting Pronouncements In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of Anti-Dilutive Share Equivalents	The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: As of June 30, 2024 2023 Stock options 351,934,688 680,112,400 Restricted stock units 251,823,915 418,580,700 Warrants 13,191,074,600 4,155,347,500 Convertible notes 1,257,860,000 —  Total 15,052,693,203 5,254,040,600	The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact: Year Ended December 31, 2023 2022 Stock options 651,237,400 513,673,885 Restricted stock units 385,954,925 21,475,400 Warrants 4,240,447,500 4,155,347,500 Total 5,277,639,825 4,690,496,785

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of financial liabilities measured at fair value on a recurring basis	The following table presents information about the Company’s financial liabilities measured at fair value on a re cu June 30, 2024 (In thousands) Total Level 1 Level 2 Level 3 Liabilities Warrant liability - Series A $ —  $ —  $ —  $ —  Warrant liability - Series B 755 —  —  755 Total liabilities $ 755 $ —  $ —  $ 755 December 31, 2023 (In thousands) Total Level 1 Level 2 Level 3 Liabilities Warrant liability - Series A $ 15 $ —  $ —  $ 15 Warrant liability - Series B 1,238 —  —  1,238 Total liabilities $ 1,253 $ —  $ —  $ 1,253	The following table presents information about the Company’s financial liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such values: December 31, 2023 (In thousands) Total Level 1 Level 2 Level 3 Liabilities Warrant liability - Series A $ 15 $ —  $ —  $ 15 Warrant liability - Series B 1,238 —  —  1,238 Total liabilities $ 1,253 $ —  $ —  $ 1,253 December 31, 2022 (In thousands) Total Level 1 Level 2 Level 3 Liabilities Warrant liability - Series A $ 1,812 $ —  $ —  $ 1,812 Warrant liability - Series B 6,040 —  —  6,040 Total liabilities $ 7,852 $ —  $ —  $ 7,852
Schedule of activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3)	The following table summarizes the activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) during the six months ended June 30, 2024: Warrant Liability (In thousands) Series A Series B Total Balance, December 31, 2023 $ 15 $ 1,238 $ 1,253 Change in the fair value of liability (15 ) (483 ) (498 ) Balance, June 30, 2024 $ —  $ 755 $ 755	The following table summarizes the activity in the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) during the years ended December 31, 2023 and 2022: Warrant Liability (In thousands) Series A Series B Total Balance, December 31, 2021 $ —  $ —  $ —  Issuance of warrants 5,285 9,513 14,798 Change in the fair value of liability (3,473 ) (3,473 ) (6,946 ) Balance, December 31, 2022 $ 1,812 $ 6,040 $ 7,852 Change in the fair value of liability (1,797 ) (4,802 ) (6,599 ) Balance, December 31, 2023 $ 15 $ 1,238 $ 1,253
Schedule of assumptions used for the fair value calculations of the warrants	Below are the assumptions used for the fair value calculations of the Series A Warrants and Series B Warrants (each defined below), as of June 30, 2024 and December 31, 2023: June 30, 2024 December 31, 2023 Series A Series B Series A Series B Stock (ADS) price $ 2.70 $ 2.70 $ 3.12 $ 3.12 Exercise price $ 17.00 $ 17.00 $ 17.00 $ 17.00 Expected term (in years) 0.2 5.2 0.7 5.7 Expected volatility 135.0 % 85.0 % 85.0 % 95.0 % Risk-free interest rate 5.5 % 4.3 % 5.1 % 3.9 % Expected dividend yield —  —  —  —	Below are the assumptions used for the fair value calculations of the Series A Warrants and Series B Warrants (each defined below), as of December 31, 2023 and 2022, adjusted, where applicable, to reflect the ADS Ratio Change for all periods presented, as more fully described in Note 1: December 31, 2023 December 31, 2022 Series A Series B Series A Series B Stock (ADS) price $ 3.12 $ 3.12 $ 9.40 $ 9.40 Exercise price $ 17.00 $ 17.00 $ 17.00 $ 17.00 Expected term (in years) 0.7 5.7 1.7 6.7 Expected volatility 85.0 % 95.0 % 80.0 % 120.0 % Risk-free interest rate 5.1 % 3.9 % 4.4 % 4.0 % Expected dividend yield —  —  —  —

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consisted of the following as of June 30, 2024 and December 31, 2023: ($ in thousands) June 30, December 31, Employee compensation and benefits $ 377 $ 187 External research and development expenses 446 635 Professional and consulting fees 363 669 Restructuring 458 —  Other 41 75 Total accrued expenses $ 1,685 $ 1,566	Accrued expenses consisted of the following as of December 31, 2023 and 2022: ($ in thousands) December 31, December 31, Employee compensation and benefits $ 187 $ 1,426 External research and development expenses 635 1,446 Professional and consulting fees 669 148 Other 75 128 Total accrued expenses $ 1,566 $ 3,148

Shareholders' (Deficit) Equity

Shareholders' (Deficit) Equity (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Schedule of summarizes the outstanding warrants	The following table summarizes the Company’s outstanding warrants as of June 30, 2024 and December 31, 2023: Number of Warrant ADSs June 30, December 31, Weighted- Expiration Date Equity-classified Warrants 2019 Investor Warrants 59,211 59,211 $ 60.00 7/1/2024 2019 Placement Warrants —  8,881 $ 57.00 6/28/2024 2020 Investor Warrants 139,882 139,882 $ 44.00 Feb-Mar 2025 2020 Placement Warrants 22,481 22,481 $ 51.00 Feb-Mar July 2021 Placement Agent Warrants 19,919 19,919 $ 46.40 7/7/2026 December 2021 Investor Warrants 107,775 107,775 $ 33.00 1/4/2027 December 2021 Placement Agent Warrants 8,622 8,622 $ 35.00 12/29/2026 March 2022 Investor Warrants 186,020 186,020 $ 28.00 3/10/2027 March 2022 Placement Agent Warrants 14,882 14,882 $ 30.00 3/10/2027 October 2023 Investor Prefunded Warrants 48,387 48,387 $ 0.20 — October 2023 Placement Agent Warrants 42,550 42,550 $ 4.13 10/6/2028 March 2024 Placement Agent Warrants 132,061 —  $ 1.85 3/27/2029 May 2024 Investor Warrants 4,029,754 —  $ 1.77 May-Jun 2027 May 2024 Placement Agent Warrants 322,380 —  $ 1.89 5/31/2029 5,133,924 658,610 Liability-classified Warrants September 2022 Series A Investor Warrants 755,000 755,000 $ 17.00 9/14/2024 September 2022 Series B Investor Warrants 755,000 755,000 $ 17.00 9/14/2029 1,510,000 1,510,000 Total outstanding 6,643,924 2,168,610 The following table summarizes the Company’s warrants activity for the six months ended June 30, 2024: ($ in thousands, except per share data) Number of Weighted-Average Outstanding at December 31, 2023 2,168,610 $ 21.97 Issued 4,484,195 1.78 Exercised —  —  Expired (8,881 ) 57.00 Outstanding at June 30, 2024 6,643,924 $ 8.30	The following table summarizes the Company’s outstanding warrants as of December 31, 2023 and 2022: Number of Warrant ADSs December 31, December 31, Weighted- Expiration Date Equity-classified Warrants 2019 Investor Warrants 59,211 59,211 $ 60.00 7/1/2024 2019 Placement Warrants 8,881 8,881 $ 57.00 6/28/2024 2020 Investor Warrants 139,882 139,882 $ 44.00 Feb-Mar 2025 2020 Placement Warrants 22,481 22,481 $ 51.00 Feb-Mar July 2021 Placement Agent Warrants 19,919 19,919 $ 46.40 7/7/2026 December 2021 Investor Warrants 107,775 107,775 $ 33.00 1/4/2027 December 2021 Placement Agent Warrants 8,622 8,622 $ 35.00 12/29/2026 March 2022 Investor Warrants 186,020 186,020 $ 28.00 3/10/2027 March 2022 Placement Agent Warrants 14,882 14,882 $ 30.00 3/10/2027 October 2023 Investor Prefunded Warrants 48,387 —  $ 0.20 — October 2023 Placement Agent Warrants 42,550 —  $ 4.13 10/6/2028 658,610 567,673 Liability-classified Warrants September 2022 Series A Investor Warrants 755,000 755,000 $ 17.00 9/14/2024 September 2022 Series B Investor Warrants 755,000 755,000 $ 17.00 9/14/2029 1,510,000 1,510,000 Total outstanding 2,168,610 2,077,673 The following table summarizes the Company’s warrants activity for the year ended December 31, 2023: ($ in thousands, except per share data) Number of Weighted-Average Outstanding at December 31, 2022 2,077,673 $ 22.85 Issued 90,937 2.04 Exercised —  —  Expired —  —  Outstanding at December 31, 2023 2,168,610 $ 21.97

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of share option activity and related information for employees and directors	The following is a summary of the Company’s stock option activity under the 2014 Plan and the 2023 Plan for the six months ended June 30, 2024: ($ in thousands, except share and per share data) Stock Options Weighted- Weighted- Aggregate Outstanding at December 31, 2023 651,237,400 $ 0.01 8.5 $ —  Granted 25,000,000 —  Exercised —  —  Forfeited (299,802,712 ) 0.01 Expired (24,500,000 ) 0.02 Outstanding at June 30, 2024 (1) 351,934,688 $ 0.01 4.6 $ —  Exercisable at June 30, 2024 263,101,355 $ 0.01 3.2 $ —  (1) Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.	The following is a summary of the Company’s stock option activity under the 2014 Plan and the 2023 Plan for the year ended December 31, 2023: ($ in thousands, except share and per share data) Stock Weighted- Weighted- Aggregate Outstanding at December 31, 2022 513,673,885 $ 0.02 8.7 $ —  Granted 223,690,700 0.00 Exercised —  —  Forfeited (27,127,185 ) 0.03 Expired (59,000,000 ) 0.04 Outstanding at December 31, 2023 (1) 651,237,400 $ 0.01 8.5 $ —  Exercisable at December 31, 2023 212,510,100 $ 0.02 7.6 $ —  (1) Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.
Schedule of assumptions used to determine the fair value of stock granted	The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis: 2024 2023 Expected volatility 98.0 % 99.3 % Risk-free interest rate 4.3 % 3.8 % Expected dividend yield —  —  Expected term (in years) 5.5 6.0	The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis: 2023 2022 Expected volatility 98.7 % 76.1 % Risk-free interest rate 3.8 % 3.1 % Expected dividend yield —  —  Expected term (in years) 6.0 6.1
Summary of activity of the Company's unvested RSUs	The following table summarizes the Company’s RSU activity for the six months ended June 30, 2024: Time-based Awards ($ in thousands, except per share data) Number of Weighted-Average Nonvested shares at December 31, 2023 385,954,925 $ 0.00 Granted 731,393,807 0.00 Forfeited (482,249,417 ) 0.00 Vested (383,275,400 ) 0.00 Nonvested shares at June 30, 2024 251,823,915 $ 0.00	The following table summarizes the Company’s restricted stock activity for the year ended December 31, 2023: Time-based Awards ($ in thousands, except per share data) Number of Shares Weighted-Average Nonvested shares at December 31, 2022 21,475,400 $ 0.01 Granted 407,843,000 0.00 Forfeited —  —  Vested (43,363,475 ) 0.01 Nonvested shares at December 31, 2023 385,954,925 $ 0.00
Schedule of stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss	Total share-based compensation expense attributable to share-based payments made to employees, consultants and directors included in operating expenses in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023, was as follows: Three Months Ended Six Months Ended ($ in thousands) 2024 2023 2024 2023 Research and development $ 13 $ 32 $ 56 $ 63 General and administrative 147 244 400 478 Restructuring and other costs 285 —  285 —  Total share-based compensation expense $ 445 $ 276 $ 741 $ 541	Total stock-based compensation expense attributable to stock-based payments made to employees, consultants and directors included in operating expenses in the Company’s consolidated statements of operations and comprehensive loss for the years ended December 31, 2023 and 2022, was as follows: Year Ended December 31, ($ in thousands) 2023 2022 Research and development $ 153 $ 120 General and administrative 997 615 Total stock-based compensation expense $ 1,150 $ 735

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of components of income/(loss) before income taxes	The components of net loss before income tax are as follows: Year Ended December 31, 2023 2022 Domestic (UK) $ (10,267 ) $ (18,018 ) Foreign 259 270 Net loss before income tax $ (10,008 ) $ (17,748 )
Schedule of components of income tax expense	The components of income tax expense are as follows: Year Ended December 31, 2023 2022 Current income taxes Domestic (UK) $ —  $ —  U.S. —  —  Foreign —  —  Deferred income taxes Domestic (UK) —  —  Foreign —  —  Income tax expense $ —  $ —
Schedule of deferred tax assets and liabilities	As of December 31, 2023 and 2022 the tax effects of temporary differences and carryforwards that give rise to significant portions of the Company’s deferred tax assets were as follows: (in thousands) December 31, December 31, Deferred tax assets Stock-based compensation $ 480 $ 955 PP&E and other accrued liabilities 899 642 Intangibles 780 1,659 Warrant revaluation (2,895 ) (947 ) Tax loss carry forward 42,978 32,307 Total deferred tax assets 42,242 34,616 Valuation allowance (42,242 ) (34,616 ) Net deferred tax assets $ —  $ —
Schedule of income taxes at the UK statutory rate compared to the company's income tax expenses	The following is a reconciliation of income tax expense computed at the UK statutory rate (2023: 23.5% (pro-rated), Year Ended December 31, 2023 2022 Net loss before income tax $ (10,008 ) $ (17,748 ) Statutory rate 23.50 % 19.00 % Expected income tax recovery (2,352 ) (3,372 ) Impact on income tax expense/recovery from Change in valuation allowance 7,617 4,327 Permanent differences 4 408 U.S. state taxes (net of FBOS) 1,394 (1,114 ) Tax rate difference in foreign jurisdictions (974 ) (248 ) Change of tax rate due to U.S. tax reform —  4 Change in equity compensation 123 752 Change in operating losses (94 ) (133 ) Change of tax rate from prior year (6,635 ) (624 ) Deferred tax adjustments 760 —  Non-deductible 157 —  Income tax expense $ —  $ —

Description of Business (Detail

Description of Business (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024 USD ($) $ / shares	Dec. 31, 2023 USD ($) BusinessDay $ / shares	Mar. 31, 2024 $ / shares	Aug. 17, 2023 $ / shares shares	Aug. 16, 2023 shares	Jun. 30, 2023 $ / shares	Mar. 31, 2023 $ / shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2020 $ / shares	Dec. 31, 2020 £ / shares
Description of Business [Line Items]
Accumulated deficit	$ 240,585	$ 227,461						$ 217,453
Cash balance	4,177	$ 3,845						$ 13,250
Closing bid price (in dollars per ADS) | $ / shares		$ 1
Stockholders equity requirement	2,500	$ 2,500
Remaining shareholder's deficit required to get listed in Nasdaq listing	$ 3,700	$ 200
Ordinary shares, par value | (per share)	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	£ 0.01
Number of ordinary shares representing one american depositary share | shares				2,000	100
Minimum
Description of Business [Line Items]
Threshold consecutive trading day period for bid | BusinessDay		10

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Antidilutive securities excluded from computation of earnings per share (Details) (Details) - shares	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share [Line Items]
Total	15,052,693,203	5,254,040,600	5,277,639,825	4,690,496,785
Stock options
Earnings Per Share [Line Items]
Total	351,934,688	680,112,400	651,237,400	513,673,885
Warrants
Earnings Per Share [Line Items]
Total	13,191,074,600	4,155,347,500	4,240,447,500	4,155,347,500
Restricted stock units
Earnings Per Share [Line Items]
Total	251,823,915	418,580,700	385,954,925	21,475,400
Convertible notes
Earnings Per Share [Line Items]
Total	1,257,860,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)				3 Months Ended		6 Months Ended		12 Months Ended
	May 10, 2024	May 01, 2024	Mar. 10, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Feb. 29, 2024
Summary of Significant Accounting Policies
Cash equivalents				$ 0		$ 0		$ 0	$ 0
Short-term finance				600,000		$ 600,000				$ 1,100,000
Short-term finance, interest rate										7.49%
Short-term debt, terms						monthly installments through November 2024.
Gross proceeds from convertible promissory notes						$ 1,000,000
Merger-related costs				254,000		1,298,000
Expected percentage of reduction of workforce		67%
Restructuring-related charges						1,600,000
Restructuring-related charges unpaid				500,000		500,000
May 2024 Plan
Summary of Significant Accounting Policies
Restructuring-related charges				1,600,000		1,600,000
Additional restructuring-related expenses						0
Severance and other settlement payments				1,300,000		1,300,000
Expected non cash expense relating to vesting of equity awards				300,000		$ 300,000
May 2024 Convertible Notes
Summary of Significant Accounting Policies
Gross proceeds from convertible promissory notes	$ 1,000,000
Payment terms						The May 2024 Notes bear interest at 15% per annum, which may be increased to 17% upon the occurrence of certain events of default as described therein, and the principal and all accrued but unpaid interest is due on the date that is the earlier of (a) ten (10) business days following the Company’s receipt of a U.K. research and development tax credit from HM Revenue and Customs, and (b) November 10, 2024.
Interest rate per annum	15%
Default, interest rate percentage	17%
Conversion description						Provided, however, at any time or times from the date of the note and until the tenth business day prior to closing of the Merger, the note holders are entitled to convert any portion of the outstanding and unpaid amount, including principal and accrued interest, into Company ADSs at a fixed conversion price equal to $1.59, representing the Nasdaq official closing price of the Company’s ADSs on the issuance date, subject to certain restrictions.
Conversion price	$ 1.59
Registered direct offering
Summary of Significant Accounting Policies
Aggregate ADSs issued (in shares)			372,042
Price per share			$ 24
Series A warrants | American Depositary Shares | Registered direct offering
Summary of Significant Accounting Policies
Aggregate ADSs issued (in shares)						755,000
Price per share						$ 17
Series B warrants | American Depositary Shares | Registered direct offering
Summary of Significant Accounting Policies
Aggregate ADSs issued (in shares)						755,000
Price per share						$ 17
Maximum | May 2024 Convertible Notes
Summary of Significant Accounting Policies
Interest expense				100,000		$ 100,000
Accrued interest				$ 100,000		$ 100,000
Patents [Member]
Summary of Significant Accounting Policies
Finite-Lived intangible assets, remaining amortization period				22 years		22 years		22 years
Amortization of intangible assets				$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000	$ 100,000

Agreement and Plan of Merger -

Agreement and Plan of Merger - Additional Information (Details)		6 Months Ended		12 Months Ended
	Mar. 04, 2024 USD ($) $ / shares	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2023 USD ($) $ / shares	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares	Mar. 31, 2024 $ / shares	Aug. 17, 2023 $ / shares	Mar. 31, 2023 $ / shares	Dec. 31, 2020 $ / shares	Dec. 31, 2020 £ / shares
Agreement and Plan of Merger [Line Items]
Share capital, par value | (per share)		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	£ 0.01
Cash		$ 4,177,000		$ 3,845,000	$ 13,250,000
Net proceeds from sale of shares		$ 8,820,000	$ 3,502,000	$ 7,016,000	$ 25,194,000
Akari and Peak Bio
Agreement and Plan of Merger [Line Items]
Termination fee	$ 300,000
Minimum | Akari
Agreement and Plan of Merger [Line Items]
Net proceeds from sale of shares	10,000,000
Maximum | Peak Bio
Agreement and Plan of Merger [Line Items]
Cash	13,500,000
Maximum | Akari and Peak Bio
Agreement and Plan of Merger [Line Items]
Payment for expenses related to merger transaction	$ 1,500,000
American Depository Shares
Agreement and Plan of Merger [Line Items]
Percentage of expected ownership in outstanding shares	50%
Akari Ordinary Shares
Agreement and Plan of Merger [Line Items]
Share capital, par value | $ / shares	$ 0.0001
Peak Common Stock
Agreement and Plan of Merger [Line Items]
Share capital, par value | $ / shares	$ 0.0001

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value Measurements
Financial liabilities measured at fair value	$ 755	$ 1,253	$ 7,852
Recurring | Series A warrants
Fair Value Measurements
Financial liabilities measured at fair value	0	15	1,812
Recurring | Series B warrants
Fair Value Measurements
Financial liabilities measured at fair value	755	1,238	6,040
Level 3
Fair Value Measurements
Financial liabilities measured at fair value	755	1,253	7,852
Level 3 | Recurring | Series A warrants
Fair Value Measurements
Financial liabilities measured at fair value	0	15	1,812
Level 3 | Recurring | Series B warrants
Fair Value Measurements
Financial liabilities measured at fair value	$ 755	$ 1,238	$ 6,040

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of the activity in warrant liability (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value Measurements
Fair value at beginning	$ 1,253	$ 7,852
Issuance of warrants			$ 14,798
Change in fair value of liability	(498)	(6,599)	(6,946)
Fair value at ending	755	1,253	7,852
Series A warrants
Fair Value Measurements
Fair value at beginning	15	1,812
Issuance of warrants			5,285
Change in fair value of liability	(15)	(1,797)	(3,473)
Fair value at ending	0	15	1,812
Series B warrants
Fair Value Measurements
Fair value at beginning	1,238	6,040
Issuance of warrants			9,513
Change in fair value of liability	(483)	(4,802)	(3,473)
Fair value at ending	$ 755	$ 1,238	$ 6,040

Fair Value Measurements - Assum

Fair Value Measurements - Assumptions used for the fair value calculations of warrants (Details)	Jun. 30, 2024 USD ($) shares	Dec. 31, 2023 shares USD ($)	Dec. 31, 2022 USD ($) shares
Series A warrants | Exercise price
Fair Value Measurements
Warrants outstanding, measurement input	17	17	17
Series A warrants | Volatility
Fair Value Measurements
Warrants outstanding, measurement input	135	85	80
Series A warrants | Stock price
Fair Value Measurements
Warrants outstanding, measurement input | shares	2.7	3.12	9.4
Series A warrants | Risk-free rate
Fair Value Measurements
Warrants outstanding, measurement input	5.5	5.1	4.4
Series A warrants | Expected term (in years)
Fair Value Measurements
Warrants outstanding, measurement input	0.2	0.7	1.7
Series B warrants | Exercise price
Fair Value Measurements
Warrants outstanding, measurement input	17	17	17
Series B warrants | Volatility
Fair Value Measurements
Warrants outstanding, measurement input	85	95	120
Series B warrants | Stock price
Fair Value Measurements
Warrants outstanding, measurement input | shares	2.7	3.12	9.4
Series B warrants | Risk-free rate
Fair Value Measurements
Warrants outstanding, measurement input	4.3	3.9	4
Series B warrants | Expected term (in years)
Fair Value Measurements
Warrants outstanding, measurement input	5.2	5.7	6.7

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Accrued Liabilities, Current [Abstract]
Employee compensation and benefits	$ 377	$ 187	$ 1,426
External research and development expenses	446	635	1,446
Professional and consulting fees	363	669	148
Restructuring	458
Other	41	75	128
Total accrued expenses	$ 1,685	$ 1,566	$ 3,148

Accrued Expenses - Additional I

Accrued Expenses - Additional Information (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Restructuring Cost and Reserve [Line Items]
Accrued restructuring expenses	$ 458
One-time termination benefits
Restructuring Cost and Reserve [Line Items]
Accrued restructuring expenses	$ 500

Shareholders' (Deficit) Equit_2

Shareholders' (Deficit) Equity - Additional Information (Details) $ / shares in Units, $ in Thousands					1 Months Ended						6 Months Ended		12 Months Ended
	May 31, 2024 $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Sep. 14, 2022 USD ($) $ / shares shares	Mar. 10, 2022 USD ($) $ / shares shares	May 31, 2024 USD ($) $ / shares shares	Mar. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Jan. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Mar. 04, 2024 $ / shares	Aug. 17, 2023 $ / shares shares	Aug. 16, 2023 shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2020 £ / shares
Class of Stock [Line Items]
Number of shares authorized | shares							45,122,321,523				45,122,321,523	35,000,000,000	45,122,321,523	15,000,000,000
Proceeds from issuance of shares			$ 12,800
Net proceeds from sale of shares											$ 8,820	$ 3,502	$ 7,016	$ 25,194
Excess fair value of warrant liability over cash proceeds														$ 1,963
Nominal value of ADS (in per warrant ADS) | (per share)		$ 0.0001				$ 0.0001	$ 0.0001				$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001			$ 0.0001		$ 0.0001	£ 0.01
Number of ordinary shares representing one ADS | shares																	2,000	100
Capital redemption reserve							$ 52,194				$ 52,194		$ 52,194	$ 52,194					$ 50,600
Deferred shares issued | shares																			3,847,331,913
Deferred shares issued price per share | $ / shares																			$ 0.01315
Aggregate nominal value cancelled per share | $ / shares																			$ 0.01
Aggregate nominal value cancelled																			$ 50,600
Ordinary Shares
Class of Stock [Line Items]
Nominal value of ADS (in per warrant ADS) | $ / shares																$ 0.0001
Capital redemption reserve																			$ 1,600
ADS | Ordinary Shares
Class of Stock [Line Items]
Number of ordinary shares representing one ADS | shares												2,000
ADS | Series C Warrants
Class of Stock [Line Items]
Purchase price of share | $ / shares					$ 1.885
Warrants issued to purchase ADS (in shares) | shares	4,029,754				4,029,754
Term of the warrants	3 years				3 years
Private Placement | Placement agent
Class of Stock [Line Items]
Estimated fair value of the placement agent warrants					$ 400	$ 200		$ 100
Private Placement | ADS
Class of Stock [Line Items]
Aggregate ADSs issued (in shares) | shares	4,029,754					1,320,614	947,868	551,816
Price per share | $ / shares						$ 1.48	$ 2.11	$ 3.3
Aggregate gross proceeds					$ 7,600
Percentage of the price per ADS for exercise price						125%		125%
Warrant expiration date	May 31, 2029				May 31, 2029			Oct. 06, 2028
Net proceeds from sale of shares					$ 7,000	$ 1,700	$ 1,800
Gross proceeds from private placement						$ 2,000	$ 2,000
Warrants issued to purchase ADS (in shares) | shares	332,380				332,380	132,061		42,550
Exercise price of warrants | $ / shares	$ 1.885				$ 1.885	$ 1.85		$ 4.13
Private Placement | ADS | Pre-Funded Warrants
Class of Stock [Line Items]
Purchase price of share | $ / shares								$ 3.1
Aggregate gross proceeds								$ 2,000
Net proceeds from sale of shares								$ 1,700
Warrants issued to purchase ADS (in shares) | shares								48,387
Exercise price of warrants | $ / shares								$ 0.2
Private Placement | ADS | Series C Warrants
Class of Stock [Line Items]
Exercise price of warrants | $ / shares	1.76				1.76
Private Placement | ADS | Series C Warrants | Dr. Prudo and Dr. Patel
Class of Stock [Line Items]
Exercise price of warrants | $ / shares	$ 1.79				$ 1.79
Registered direct offering
Class of Stock [Line Items]
Aggregate ADSs issued (in shares) | shares				372,042
Price per share | $ / shares				$ 24
Proceeds from issuance of shares				$ 8,900
Grant date fair value of warrants			14,800
Excess fair value of warrant liability over cash proceeds			$ 2,000
Registered direct offering | Investor warrants
Class of Stock [Line Items]
Warrants issued to purchase ADS (in shares) | shares				186,020
Exercise price of warrants | $ / shares				$ 28
Term of the warrants				5 years
Registered direct offering | Placement agent
Class of Stock [Line Items]
Warrants issued to purchase ADS (in shares) | shares				14,882
Amount paid for placement agent fees and expenses				$ 800
Exercise price of warrants | $ / shares				$ 30
Registered direct offering | ADS
Class of Stock [Line Items]
Aggregate ADSs issued (in shares) | shares		1,333,333	755,000
Price per share | $ / shares		$ 3	$ 17
Proceeds from issuance of shares		$ 4,000	$ 12,800
Net proceeds from sale of shares		$ 3,500
Registered direct offering | ADS | Series A warrants
Class of Stock [Line Items]
Warrants issued to purchase ADS (in shares) | shares			755,000
Share issue price (in dollars per ADS) | $ / shares			$ 17
Registered direct offering | ADS | Series B warrants
Class of Stock [Line Items]
Warrants issued to purchase ADS (in shares) | shares			755,000
Share issue price (in dollars per ADS) | $ / shares			$ 17
Registered Offering
Class of Stock [Line Items]
Proceeds from issuance of shares									$ 4,900	$ 6,000					$ 1,100
Net proceeds from sale of shares										$ 5,400				$ 4,300
Registered Offering | ADS
Class of Stock [Line Items]
Aggregate ADSs issued (in shares) | shares										215,550
Price per share | $ / shares										$ 28
Registered Offering | ADS | Investor warrants
Class of Stock [Line Items]
Warrants issued to purchase ADS (in shares) | shares										107,775					107,775
Exercise price of warrants | $ / shares										$ 33					$ 33
Registered Offering | ADS | Placement agent
Class of Stock [Line Items]
Warrants issued to purchase ADS (in shares) | shares										8,622					8,622
Exercise price of warrants | $ / shares										$ 35					$ 35

Shareholders' (Deficit) Equit_3

Shareholders' (Deficit) Equity - outstanding warrants (Details) - American Depositary Shares - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024
Class of Warrant or Right [Line Items]
Equity-classified Warrants	5,133,924	658,610	567,673
Liability-classified Warrants	1,510,000	1,510,000	1,510,000
Warrants exercised	6,643,924	2,168,610	2,077,673
2019 Investor Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		59,211	59,211	59,211
Weighted-Average Exercise Price	$ 60	$ 60
2019 Placement Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		8,881	8,881	0
Weighted-Average Exercise Price	57	$ 57
2020 Investor Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		139,882	139,882	139,882
Weighted-Average Exercise Price	44	$ 44
2020 Placement Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		22,481	22,481	22,481
Weighted-Average Exercise Price	51	$ 51
July 2021 Placement Agent Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		19,919	19,919	19,919
Weighted-Average Exercise Price	46.4	$ 46.4
December 2021 Investor Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		107,775	107,775	107,775
Weighted-Average Exercise Price	33	$ 33
December 2021 Placement Agent Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		8,622	8,622	8,622
Weighted-Average Exercise Price	35	$ 35
March 2022 Investor Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		186,020	186,020	186,020
Weighted-Average Exercise Price	28	$ 28
March 2022 Placement Agent Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		14,882	14,882	14,882
Weighted-Average Exercise Price	30	$ 30
October 2023 Investor Prefunded Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		48,387		48,387
Weighted-Average Exercise Price	0.2	$ 0.2
October 2023 Placement Agent Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants		42,550		42,550
Weighted-Average Exercise Price	$ 4.13	$ 4.13
May 2024 Investor Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants	4,029,754
Weighted-Average Exercise Price	$ 1.77
May 2024 Placement Agent Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants	322,380
Weighted-Average Exercise Price	$ 1.89
March 2024 Placement Agent Warrants
Class of Warrant or Right [Line Items]
Equity-classified Warrants				132,061
Weighted-Average Exercise Price	$ 1.85
Series A warrants | September 2022 Investor Warrants
Class of Warrant or Right [Line Items]
Liability-classified Warrants	755,000	755,000	755,000
Weighted-Average Exercise Price	$ 17	$ 17
Series B warrants | September 2022 Investor Warrants
Class of Warrant or Right [Line Items]
Liability-classified Warrants	755,000	755,000	755,000
Weighted-Average Exercise Price	$ 17	$ 17

Shareholders' (Deficit) Equit_4

Shareholders' (Deficit) Equity - Summary of Company"s Warrants Activity (Details) - Warrant [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Warrants Outstanding Beginning Balance	2,168,610	2,077,673
Number of Warrants, Issued	4,484,195	90,937
Number of Warrants, Expired	(8,881)
Number of Warrants Outstanding, Ending Balance	6,643,924	2,168,610
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 21.97	$ 22.85
Weighted-Average Exercise Price, Issued	1.78	2.04
Weighted-Average Exercise Price, Expired	57
Weighted Average Exercise Price Outstanding, Ending Blance	$ 8.3	$ 21.97

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
2023 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of ordinary shares underlying outstanding equity awards consisting of stock options and restricted stock units	318,823,915	247,798,825
Number of shares available to grant		765,819,200
Number of shares remained available for future issuance	724,581,522
2023 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to issue			980,000,000
2023 and 2014 Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair market value of shares	100%	100%
2023 and 2014 Plans | Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	1 year	1 year
2023 and 2014 Plans | Minimum | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	2 years	2 years
2023 and 2014 Plans | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of awards (in years)	10 years	10 years
2023 and 2014 Plans | Maximum | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	4 years	4 years
Equity Incentive Plan 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of ordinary shares underlying outstanding equity awards consisting of stock options and restricted stock units	284,934,688	789,393,500	855,637,300
Equity Incentive Plan 2014 | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to issue		1,835,637,300
Number of shares available to grant			855,637,300

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Activity (Details) - 2023 and 2014 Plans - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Options Outstanding at beginning of the period	651,237,400	513,673,885
Number of shares, Granted	25,000,000	223,690,700
Number of shares, Forfeited	(299,802,712)	(27,127,185)
Number of shares, Expired	(24,500,000)	(59,000,000)
Number of shares, Options Outstanding at end of the period	351,934,688	651,237,400	513,673,885
Number of shares, Exercisable options at end of the period	263,101,355	212,510,100
Weighted average exercise price, Outstanding at beginning of the period	$ 0.01	$ 0.02
Weighted average exercise price, Granted		0
Weighted average exercise price, Forfeited	0.01	0.03
Weighted average exercise price, Expired	0.02	0.04
Weighted average exercise price, Outstanding at end of the period	0.01	0.01	$ 0.02
Options exercisable at end of the period, Weighted average exercise price	$ 0.01	$ 0.02
Weighted average remaining contractual life, Options outstanding during the period (in years)	4 years 7 months 6 days	8 years 6 months	8 years 8 months 12 days
Weighted average remaining contractual term, Options exercisable at end of the period (in years)	3 years 2 months 12 days	7 years 7 months 6 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value per share of options granted	$ 0.01	$ 0.01

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions used for the fair value of stock awards (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	98%	99.30%	98.70%	76.10%
Risk-free interest rate	4.30%	3.80%	3.80%	3.10%
Expected term (in years)	5 years 6 months	6 years	6 years	6 years 1 month 6 days
Restricted stock units | Equity Incentive Plan 2014 | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	1 year		1 year
Restricted stock units | Equity Incentive Plan 2014 | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	4 years		4 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summarize the activity of the company unvested RSUs (Details) - Restricted stock units - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Shares/ Units
Unvested at beginning of the period (in shares)	385,954,925	21,475,400	21,475,400
Granted (in shares)	731,393,807		407,843,000
Vested (in shares)	(383,275,400)		(43,363,475)
Unvested at end of the period (in shares)	251,823,915		385,954,925	21,475,400
Forfeited (in shares)	(482,249,417)
Weighted average grant date fair value per share
Weighted average grant date fair value per share, Beginning of the period (per share)	$ 0	$ 0.01	$ 0.01
Granted (per share)	0		0
Forfeited (per share)	0
Vested (per share)	0		0.01
Weighted average grant date fair value per share, End of the period (per share)	$ 0		$ 0	$ 0.01
Equity Incentive Plan 2014
Weighted average grant date fair value per share
Fair value of time-based RSUs that vested	$ 500	$ 100	$ 200	$ 0
Shares underlying vested	290,937,175		28,151,775

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation expense	$ 445	$ 276	$ 741	$ 541	$ 1,150	$ 735
Weighted average period					2 years 4 months 24 days
Unvested Stock Option
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation	200		$ 200		$ 1,700
Weighted average period			1 year 9 months 18 days
Restricted stock units
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation	$ 200		$ 200		600
Weighted average period			1 year 8 months 12 days
Shares underlying unvested	276,000,000		276,000,000
Additional stock-based compensation expense	$ 300		$ 300
Research and development expenses
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation expense	13	32	56	63	153	120
General and administrative expenses
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation expense	147	$ 244	400	$ 478	$ 997	$ 615
Restructuring and other costs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total share-based compensation expense	$ 285		$ 285

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Consulting charges						$ 0
Interim Ceo Agreement
Related Party Transaction [Line Items]
Payment to CEO upon aggrement	$ 50,000
Issuance of share capital for services		$ 100,000		$ 100,000
Issuance of share capital for services (in shares)		91,396,000		91,396,000
The Doctors Laboratory
Related Party Transaction [Line Items]
Operating Lease, Expense						100,000	$ 100,000
The Doctors Laboratory | Maximum
Related Party Transaction [Line Items]
Operating Lease, Expense		$ 100,000	$ 100,000	$ 100,000	$ 100,000
Related party
Related Party Transaction [Line Items]
Laboratory testing services charges						100,000	100,000
Related party | Maximum
Related Party Transaction [Line Items]
Laboratory testing services charges		100,000	$ 100,000	100,000	$ 100,000
Consulting charges							100,000
Payable balances		$ 100,000		$ 100,000		$ 100,000	$ 100,000

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Rental expense					$ 200,000	$ 200,000
Lease costs	$ 100,000	$ 100,000	$ 200,000	$ 100,000
Employee Benefit Plans
Loss Contingencies [Line Items]
Description of employee benefit plans			Under the plan, the Company matches 100% of employees’ contributions up to 5% of the annual eligible compensation contributed by each employee, subject to Internal Revenue Code limitations.		Under the plan, the Company matches 100% of employees’ contributions up to 5% of annual eligible compensation contributed by each employee, subject to Internal Revenue Code limitations.
Maximum annual eligible compensation contributed by each employee			5%		5%
Operating Expenses					$ 200,000	$ 200,000
Employee Benefit Plans | Maximum
Loss Contingencies [Line Items]
Operating Expenses	$ 100,000			$ 100,000
Employee Benefit Plans | U.K.
Loss Contingencies [Line Items]
Description of employee benefit plans			The Company also adopted a defined contribution pension scheme which allows for U.K. employees to make contributions and provides U.K. employees with a Company contribution of 10% of compensation, subject to U.K. law.		The Company also adopted a defined contribution pension scheme which allows for U.K. employees to make contributions and provides U.K. employees with a Company contribution of 10% of compensation, subject to U.K. law.
Maximum annual eligible compensation contributed by each employee			10%		10%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Domestic (UK)	$ (10,267)	$ (18,018)
Foreign	259	270
Net loss before income tax	$ (10,008)	$ (17,748)

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets
Stock-based compensation	$ 480	$ 955
PP&E and other accrued liabilities	899	642
Intangibles	780	1,659
Warrant revaluation	(2,895)	(947)
Tax loss carry forward	42,978	32,307
Total deferred tax assets	42,242	34,616
Valuation allowance	$ (42,242)	$ (34,616)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands			12 Months Ended
	Apr. 01, 2023	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	25%	19%	23.50%	19%
Effective Income Tax Rate Reconciliation, Tax Credit, Percent			14.50%
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefits			$ 0	$ 0
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Unrecognized tax benefits			0	$ 0
US State
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			60,300
Operating loss unlimited carryforward amount			$ 29,200
United Kingdom
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			25%
Operating loss carryforwards			$ 125,200
United States
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21%
Operating loss carryforwards			$ 33,500
Operating loss unlimited carryforward amount			27,700
Switzerland | Maximum
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards			$ 100

Income Taxes - Income taxes at

Income Taxes - Income taxes at the UK statutory rate compared to the Company's income tax expenses (Details) - USD ($)			12 Months Ended
	Apr. 01, 2023	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Net loss before income tax			$ (10,008)	$ (17,748)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	25%	19%	23.50%	19%
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount			$ (2,352)	$ (3,372)
Impact on income tax expense/recovery from
Change in valuation allowance			7,617	4,327
Permanent differences			4	408
U.S. state taxes (net of FBOS)			1,394	(1,114)
Tax rate difference in foreign jurisdictions			(974)	(248)
Change of tax rate due to U.S. tax reform				4
Change in equity compensation			123	752
Change in operating losses			(94)	(133)
Change of tax rate from prior year			(6,635)	$ (624)
Deferred tax adjustments			760
Non-deductible transaction costs			157
Income tax expense			$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Details)		1 Months Ended	6 Months Ended		12 Months Ended
	Mar. 04, 2024 USD ($) $ / shares	Mar. 31, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares	Jun. 30, 2023 USD ($) $ / shares	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares	Mar. 01, 2024	Aug. 17, 2023 $ / shares	Mar. 31, 2023 $ / shares	Dec. 31, 2020 $ / shares	Dec. 31, 2020 £ / shares
Subsequent Event [Line Items]
Net proceeds from sale of shares			$ 8,820,000	$ 3,502,000	$ 7,016,000	$ 25,194,000
Share capital, par value | (per share)		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001	£ 0.01
Cash			$ 4,177,000		$ 3,845,000	$ 13,250,000
Akari and Peak Bio
Subsequent Event [Line Items]
Termination fee	$ 300,000
Maximum | Peak Bio
Subsequent Event [Line Items]
Cash	13,500,000
Maximum | Akari and Peak Bio
Subsequent Event [Line Items]
Payment for expenses related to merger transaction	$ 1,500,000
American Depository Shares
Subsequent Event [Line Items]
Percentage of expected ownership in outstanding shares	50%
Subsequent Event | Akari and Peak Bio
Subsequent Event [Line Items]
Termination fee	$ 300,000
Subsequent Event | Minimum
Subsequent Event [Line Items]
Net proceeds from sale of shares	10,000,000
Subsequent Event | Maximum | Peak Bio
Subsequent Event [Line Items]
Cash	$ 13,500,000
Subsequent Event | American Depository Shares
Subsequent Event [Line Items]
Price per share | $ / shares		$ 1.48
Percentage of expected ownership in outstanding shares	50%
Private Placement | Subsequent Event | American Depository Shares
Subsequent Event [Line Items]
Aggregate ADSs issued (in shares) | shares		1,320,614
Aggregate gross proceeds		$ 2,000,000
Net proceeds from sale of shares		$ 1,700,000
Akari Ordinary Shares
Subsequent Event [Line Items]
Share capital, par value | $ / shares	$ 0.0001
Akari Ordinary Shares | Subsequent Event
Subsequent Event [Line Items]
Share capital, par value | $ / shares	0.0001
Percentage of expected ownership in outstanding shares							39.51%
Peak Common Stock
Subsequent Event [Line Items]
Share capital, par value | $ / shares	0.0001
Peak Common Stock | Subsequent Event
Subsequent Event [Line Items]
Share capital, par value | $ / shares	$ 0.0001
Percentage of expected ownership in outstanding shares							39.30%